




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07D 487/04, 495/04, 207/34 C07D 403/06, 209/58 A61K 31/40 // (C07D 487/04 C07D 209:00, 209:00) (C07D 495/04, 307:00, 209:00)</p>	A1	<p>(11) International Publication Number: WO 94/02483</p> <p>(43) International Publication Date: 3 February 1994 (03.02.94)</p>
<p>(21) International Application Number: PCT/GB93/01512</p> <p>(22) International Filing Date: 19 July 1993 (19.07.93)</p> <p>(30) Priority data: 9215361.8 20 July 1992 (20.07.92) GB</p> <p>(71) Applicants (for all designated States except US): THE WELLCOME FOUNDATION LIMITED [GB/GB]; Unicorn House, 160 Euston Road, London NW1 2BP (GB). UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED [GB/GB]; Tower Building, Park Place, Cardiff CF1 3XR (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only) : FRANZMANN, Karl, Witold [GB/GB]; STABLES, Jeremy, Nigel [GB/GB]; The Wellcome Foundation Limited, Langley Court, Beckenham, Kent BR3 3BS (GB). SHANNON, Patrick, Vivian, Richard [GB/GB]; Malverns, 11 Clive Street, Penarth, South Glamorgan CF64 1AT (GB). RAO, Nagara-ja, Kodanda, Ranganatha [IN/GB]; 17 Dryburgh Avenue, Birchgrove, Cardiff CF4 4QN (GB). CHUNCHAT-PRASERT, Laddawan [TH/TH]; 244/6 Yooyen Village, Mitraparp Road, Khon Kaen 40000 (TH).</p>		<p>(74) Agent: ROLLINS, Anthony, John; The Wellcome Foundation Limited, Langley Court, Beckenham, Kent BR3 3BS (GB).</p> <p>(81) Designated States: AU, BG, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published With international search report.</p>
<p>(54) Title: TETRACYCLIC COMPOUNDS PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOUR AGENTS</p> <div style="text-align: center; margin: 20px 0;">  <p>(I)</p> </div> <p>(57) Abstract</p> <p>The present invention relates to heterocyclic compounds of formula (I), which have been found to have anti-tumour activity. More specifically, the invention concerns Pyrrolo [3,2-b] carbazoles, 1H-Benzofuro [3,2-f] indoles and 1H-[1] Benzothieno [2,3-f] indoles, methods for their preparation, intermediates, pharmaceutical formulations containing them and their use as anti-tumour agents.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

TETRACYCLIC COMPOUNDS PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOUR AGENTS

The present invention relates to heterocyclic compounds which have been found to have anti-tumour activity. More specifically, the invention concerns Pyrrolo [3,2-b] carbazoles, 1H-Benzofuro [3,2-f] indoles and 1H-[1] Benzothieno [2,3-f] indoles, methods for their preparation, pharmaceutical formulations containing them and their use as anti-tumour agents.

Research in the area of cancer chemotherapy has produced a variety of anti-tumour agents, which have differing degrees of efficacy. Standard clinically used agents include adriamycin, actinomycin D, methotrexate, 5-fluorouracil, cis-platinum, vincristine and vinblastine. However, these presently available anti-tumour agents are known to have various disadvantages, such as toxicity to healthy cells and resistance to certain tumour types.

There thus exists a continuing need to develop new and improved anti-tumour agents.

Khoshtariya et al, khim. Geterotsikl. Soedin (1980), (2) 203-8, disclose the synthesis of certain indolobenzo[b] thiophenes.


Khoshtariya et al, khim Geterotsikl Soedin (1984), (10) 1366-70 disclose the synthesis of certain indolobenzo[b] furans.

Kakhabrishvili et al, khim Geterotsikl Soedin (1985), (3) 355-8 disclose the synthesis of certain derivatives of indolo[5,6-d] and indolo [5,4-d] benzo[b] furans

The patent specification EP447,703 discloses the synthesis of certain benzo(5,6-b)benzofuran-2-carboxylates.


There have now been discovered novel compounds which exhibit anti-tumour cell activity with low toxicity against normal cell lines.

Thus, in a first aspect the present invention provides a compound of the general formula (1)



and salts and physiologically functional derivatives thereof,

wherein A is



X is O, S, SO, SO₂, CH₂, CO or NR⁷, wherein R⁷ is H, alkyl, aralkyl, aryl, alkenyl, acyl, alkynyl, sulphonyl or substituted sulphonyl;

Y is O, S, SO, SO₂, CH₂, CO or NR⁷;

R¹ is COR⁸, COOR⁸, CHO, CH₂OH, CH₂OR⁹, CONH₂, CONHNR¹⁰R¹¹, CONHR¹⁰, CONR¹⁰R¹¹, COO(CH₂)_nNR¹⁰R¹¹, wherein R⁸ is H, alkyl, aryl, substituted aryl or aralkyl, R⁹ is acyl or substituted acyl, R¹⁰ and R¹¹ are independently hydrogen, alkyl or aryl, and n is 1 to 4 carbon atoms;

R² is H, COOR⁸, alkyl, aryl, substituted aryl or CH₂CH₂CO₂R¹² wherein R¹² is alkyl or aryl;


R³ and R⁴ are independently H, hydroxy, alkyl, haloalkyl, alkoxy, halo, cyano, nitro, amino, alkyl amino, dialkyl amino, substituted alkyl, carboxyl or CO₂R¹²;

R^5 is H, alkyl, substituted alkyl, aralkyl, nitro, amino, halo, cyano, CHO, COOR⁸;

R^6 is H, aryl, alkyl, aralkyl, nitro, halogen, CHO or COR¹³ wherein R^{13} is alkyl or aryl

with the proviso that


(i) when R^2 , R^3 , R^4 , R^5 and R^6 are all H and A is



wherein Y is NH and X is O or S, then R^1 is not CO₂H or CO₂Et;

and

(ii) when R^2 , R^3 , R^4 , R^5 and R^6 are all H and A is




wherein Y is NH, and X is O then R^1 is not CHO;

and

(iii) Y is not O when X is O.

In yet a further aspect the present invention provides a compound of the general formula (1) above, wherein A is



X is O, S, SO, SO₂, CH₂, CO or NR⁷, wherein R⁷ is H, alkyl, aralkyl, aryl, alkenyl, acyl, alkynyl or sulphonyl;

Y is O, S, SO, SO₂, CH₂, CO or NR⁷;

R¹ is COOR⁸, CHO, CH₂OH, CH₂OR⁹, CONH₂, CONHR¹⁰ or CONR^{10,11}, wherein R⁸ is H, alkyl, aryl, substituted aryl or aralkyl, R⁹ is acyl or substituted acyl, and R¹⁰ and R¹¹ are independently alkyl or aryl;

R² is H, COOR⁸, alkyl, aryl, substituted aryl or CH₂CH₂CO₂R¹² wherein R¹² is alkyl or aryl;

R³ and R⁴ are independently H, hydroxy, alkyl, haloalkyl, alkoxy, halo, cyano, nitro, amino, alkyl amino, dialkyl amino, substituted alkyl, carboxyl or CO₂R¹²;

R⁵ is H, alkyl, substituted alkyl, aralkyl, nitro, halo, cyano CHO;

R⁶ is H, alkyl, aralkyl, nitro, halo, CHO or COR¹³ wherein R¹³ is alkyl or aryl with the proviso described above.

Alkyl groups present in general formula (I) may be straight or branched chain alkyl groups, and may contain 1-10 carbon atoms and suitably 1-6 carbon atoms. Examples of such alkyl groups include methyl, ethyl, t-butyl and the like.

Acyl groups may be straight or branched and may contain 1-10 carbon atoms and suitably 1-6 carbon atoms. Examples of suitable acyl groups include ethanoyl and propanoyl groups.

Alkoxy may be straight or branched and may contain 1-10 carbon atoms and suitably 1-6 carbon atoms. Examples of suitable alkoxy groups include methoxy, ethoxy and the like.

Aryl includes both carbocyclic aryl groups and heterocyclic aryl groups normally containing a maximum of 10 ring atoms. Carbocyclic aryl groups include, eg phenyl and naphthyl and contain at least one aromatic ring. Heterocyclic aryl groups include eg thienyl, furyl, pyridyl, indole and quinoline rings.

An aralkyl group may contain from 1 to 4 atoms in the alkyl portion and the aryl portion may be a carbocyclic or heterocyclic aryl group.

Substituents which may be present on the alkyl, aryl or acyl groups include alkyl, alkoxy, halo, sulphinyl, amino (optionally substituted by one or two alkyl groups), haloalkyl (eg trifluoromethyl), sulphinyl, sulphonyl and cyano.

Substituents which may be present on the sulphonyl include alkyl, aryl and aralkyl.

Halogen represents fluoro, chloro, bromo or iodo.

In the compounds of formula (1)

X is preferably O, S or NR^7 , wherein R^7 is H, alkyl, sulphonyl or toluene sulphonyl;

Y is preferably NR^7 ;

R^1 is preferably COR^8 , COOR^8 , CH_2OR^9 , CONH_2 , $\text{CNHNR}^{10,11}$, CONHR^{10} , $\text{CONR}^{10,11}$, $\text{COO}(\text{CH}_2)_n\text{NR}^{10,11}$, wherein R^8 is H, alkyl, aryl, substituted aryl or aralkyl, R^9 is acyl or substituted acyl, and R^{10} and R^{11} are independently hydrogen, alkyl or aryl and n is 1 to 4 carbon atoms;


R^2 is preferably COOR^8 , alkyl or $\text{CH}_2\text{CH}_2\text{CO}_2\text{R}^{12}$ wherein R^{12} is alkyl or aryl;

R^3 and R^4 represent independently H, hydroxy, alkyl, alkoxy, halogen, cyano, substituted alkyl or carboxyl;

R^5 is preferably H or alkyl;

R^6 is preferably H, alkyl or aryl and salts and physiologically functional derivatives thereof.

X preferably represents S or NH, A is preferably



and Y preferably represents NH.

R^1 is preferably COOR^8 , with R^8 preferably being alkyl or aralkyl.

R^2 is preferably H or alkyl.

R³ is preferably H, alkoxy or Halo.

R⁴ is preferably H, alkoxy or halo.

R⁵ is preferably alkyl and

R⁶ is preferably H

and salts and physiologically functional derivatives thereof.

Particularly preferred compounds according to the present invention include:

3-Pyridyl 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate
[(3-Dimethylamino)phenyl]3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

Benzyl 1,3,4-trimethylpyrrolo[3,2-b]carbazole-2-carboxylate

Phenyl 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

3,4-Dimethyl-2-(1-imidazolylcarbonyl)pyrrolo[3,2-b]carbazole

Ethyl 3, 4-dimethylpyrrolo [3,2,-b]carbazole-2-carboxylate;

Ethyl 3,4-dimethylbenzothieno[4,5-f]indole-2-carboxylate;

Benzyl 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate;

Benzyl 8-fluoro-3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate;

Ethyl 8-fluoro-3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

Benzyl 3,4,6-trimethylpyrrolo[3,2-b]carbazole-2-carboxylate;

Ethyl 3,4,6-trimethylpyrrolo[3,2-b]carbazole-2-carboxylate;

8-Fluoro-3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylic acid

3,4-Dimethylpyrrolo[3,2-b]carbazole-2-carboxylic acid;

Ethyl 8-methoxy-3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate;

3,4,6-Trimethylpyrrolo[3,2-b]carbazole-2-carboxylic acid and

Benzyl 8-methoxy-3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate;

and physiologically functional derivatives thereof

Compounds of the general formula (I) have been tested against two specially developed cell lines which are clones of the human fibrosarcoma cell-line, HT1080. One clone, HT1080scc2, retains the transformed phenotype of the parental line, whilst the other, HT10801c, is a morphologically flat, non-tumourigenic, revertant.


Thus, the effects of potential anti-tumour compounds can be evaluated on the basis of their ability to effect detransformation in HT1080scc2 cells.

Compounds of the present invention have been found to be particularly effective in this assay system.

In addition, compounds of the present invention have been found to be effective against MCF7 human breast cancer cells, A431 Epidermoid carcinoma cells and A285 melanoma cells.


The compounds also exhibit low toxicity against normal cells.

According to a further aspect, the present invention also provides a process for preparing compounds of general formula (I), which process comprises catalysed ring closure of compounds of formula (IV) in the presence of a strong acid.



The present invention also provides for a process for preparing compounds of formula (IV) which process comprises either:


(a) Reaction of a compound of the formula (II) with a compound of the formula (III) to produce a compound of the formula (IV), wherein X, Y, R¹, R², R³, R⁴ and R⁵ are as defined herein:-



followed by catalysed ring closure.

The reaction is preferably carried out at room temperature in the presence of a strong acid, eg p-toluene sulphonic acid or montmorillonite K10 clay as a catalyst to produce a compound of the invention;

(b) Reaction of a compound of the formula (V) with a compound of the formula (III) to produce a compound of the formula (IV) followed as in (a) by catalysed ring closure.



wherein L is a leaving group. Examples of suitable leaving groups include $-\text{OCOCH}_3$, OET, $-\text{N}^+\text{Me}_3$ and halo;

(c) A one step reaction procedure, reacting a compound of the formula (II) with a compound of the formula (III) in the presence of a catalyst, to produce a compound of the invention in a single step. The preferred catalyst is montmorillonite K10 clay;

Insertion of the substituent R^1 onto the ring system for example:

(d) Carboxylation of a polyheterocyclic compound using

- (i) a carbonyl halide or
- (ii) carbon dioxide

According to known procedures (J. March, Advanced Organic Chemistry, 2nd ed, McGraw Hill, New York, 1977, p 497-498).

(e) Alternatively one can produce compounds of the formula (I) wherein R^2 is CHO by methods known to those skilled in the art, for example:-

- (i) The appropriate aromatic polyheterocycle can be reacted with a formylating agent, such as that generated by the reaction between $SnCl_4$ and Cl_2CHOCH_3 or equivalent reagents.

For example, according to the method of A. Reiche et al, Chem. Ber. 93, 88 (1960), or with other standard formylating reagents/procedures known in the art, for example, the Gatterman-Koch reaction ($CO \backslash HCl \backslash AlCl_3 \backslash CuCl$), the Gatterman reaction ($HCN \backslash HCl \backslash ZnCl_2$), and the Vilsmeier reaction ($POCl_3 \backslash PhN-(Me)CHO$ or $POCl_3 \backslash Me_2NCHO$) (J. March, Vide Supra, p 494-497); or

- (ii) The appropriate aromatic polyheterocycle, carrying a suitable functional group, said group being converted to an aldehyde group by methods known to those skilled in the art. Suitable functional groups include $CHBr_2$, CH_3 , COR^{14} , wherein R^{14} is a primary or secondary C_{1-6} alkyl group, $COOH$ or a derivative thereof such as an ester, amide, acid chloride or CN ; or

(f) Compounds of the formula (I) wherein R^1 is $CONHR^{10}$ may also be produced by the reaction of a compound wherein R^1 is $COOH$ or a suitable reactive acid derivative thereof as outlined in J. March, Vide supra. For example an acid halide can be reacted with a compound NH_2R^{10} in an inert solvent.


(g) Conversion of one compound of formula (I) into another compound of formula (I).

Compounds of the invention wherein R^1 is $COOR^8$ and R^8 is, for example, aralkyl can be converted to free acids wherein R^8 is H by reduction in the presence of H_2 and a Pd catalyst, or where R^8 is, for example, alkyl, by hydrolysis in the presence of an appropriate base e.g. caesium carbonate.


It is thereafter possible for the skilled man to synthesise ester and amide compounds within the scope of the invention by conversion of the free acids obtained, by known procedures. (See J. March, Vide Supra, p363-365).

Compounds of the invention produced as described herein can be converted to other compounds of the invention by electrophilic substitution at R^5 and/or R^6 , to introduce, for example, NO_2 , halogen and COR^{13} wherein R^{13} is as defined herein.

The above processes have been described for compounds wherein A is



The skilled man will appreciate that these are equally applicable when A is



In another aspect the invention relates to novel intermediates of the formulae (II), (III), (IV) or (V).

The compounds of the present invention are useful for the treatment of tumours. They may be employed in treating various forms of cancer of mammals including carcinomas, for instance of the stomach, pancreas, breast, uterus and colon; adenocarcinomas, for instance of the lung and colon; sarcomas, for instance fibrosarcoma; leukaemias, for instance lymphocytic leukaemia and lymphomas, for instance myeloid lymphoma.

The invention thus further provides a method for the treatment of tumours in animals, including mammals, especially humans, which comprises the administration of a clinically useful amount of compound of formula (I) or a pharmaceutically acceptable salt or physiologically functional derivative in a pharmaceutically useful form, once or several times a day or in any other appropriate schedule, orally, rectally, parenterally, or applied topically.

In addition, there is provided as a further, or alternative, aspect of the invention, a compound of formula (I) or a pharmaceutically acceptable salt or physiologically functional derivative thereof for use in therapy, for example as an antitumour agent.

The amount of compound of formula (I) required to be effective against the aforementioned tumours will, of course, vary and is ultimately at the discretion of the medical or veterinary practitioner. The factors to be considered include the condition being treated, the route of administration, and nature of the formulation, the mammal's body weight, surface area, age and general condition, and the particular compound to be administered. A suitable effective anti-tumour dose is in the range of about 0.01 to about 100 mg/kg body weight, eg 0.1 to about 100 mg/kg body weight, preferably 1-30 mg/kg body weight. The total daily dose may be given as a single dose, multiple doses, e.g., two to six times per day or by intravenous infusion for selected duration. For example, for a 75 kg mammal, the dose range would be about 8 to 900 mg per day, and a typical dose could be about 50 mg per day. If discrete multiple doses are indicated treatment might

typically be 15 mg of a compound of formula (I) given up to 4 times per day.

Whilst it is possible for the active compound to be administered alone, it is preferable to present the active compound in a pharmaceutical formulation. Formulations of the present invention, for medical use, comprise a compound of formula (I) or a salt thereof together with one or more pharmaceutically acceptable carriers and optionally other therapeutic ingredients. The carrier(s) should be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The present invention, therefore, further provides a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt or physiologically functional derivative thereof together with a pharmaceutically acceptable carrier thereof.

There is also provided a method for the preparation of a pharmaceutical formulation comprising bringing into association a compound of formula (I) or a pharmaceutically acceptable salt or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier thereof.

Formulations according to the present invention include those suitable for oral, topical, rectal or parenteral (including subcutaneous, intramuscular and intravenous) administration. Preferred formulations are those suitable for oral or parenteral administration.

The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active compound into association with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active compound into association

with a liquid carrier or a finely divided solid carrier or both and then, if necessary, shaping the product into desired formulations.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, each containing a predetermined amount of the active compound; as a powder or granules; or a solution or suspension in an aqueous or non-aqueous liquid such as a syrup, an elixir, an emulsion or a draught.

A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered active compound with any suitable carrier.

A syrup may be made by adding the active compound to a concentrated, aqueous solution of a sugar, for example sucrose, to which may also be added any accessory ingredients. Such accessory ingredients(s) may include flavourings, an agent to retard crystallisation of the sugar or an agent to increase the solubility of any other ingredients, such as a polyhydric alcohol for example glycerol or sorbitol.

Formulations for rectal administration may be presented as a suppository with a conventional carrier such as cocoa butter.

Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active compound which is preferably isotonic with the blood of the recipient. Such formulations suitably comprise a solution of a pharmaceutically and pharmacologically acceptable acid addition salt of a compound of the formula (I) that is isotonic with the blood of the recipient.

Useful formulations also comprise concentrated solutions or solids containing the compound of formula (I) which upon dilution with an appropriate solvent give a solution for parenteral administration as above.

In addition to the aforementioned ingredients, the formulations of this invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.

In a further aspect the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt or physiologically functional derivative thereof for the manufacture of a medicament for the treatment of tumours.

The invention will now be illustrated by the following non-limiting Examples:

All temperatures are in degrees Celcius ($^{\circ}\text{C}$)

IR spectra were recorded on a Perkin-Elmer 257 grating spectrophotometer or a Bruker FS66 spectrophotometer.

U.V. spectra were measured in ethanol on a Unicam SP800 spectrophotometer.

^1H NMR spectra were obtained on a Bruker WM 360-NMR spectrophotometer at 360 MHz, or on a Bruker AC200 spectrophotometer at 200 MHz. J values are given in Hz.

Mass spectra were obtained on Varian CH5D(EI), Kratos Concept (EI) or Kratos Ms50(FAB) instruments.

Example 1Preparation of IntermediatesPreparation of Pyrroles

Ethyl 4-acetyl-3,5-dimethylpyrrole-2-carboxylate, benzyl 4-acetyl-3,5-dimethylpyrrole-2-carboxylate and ethyl 4-acetyl-3-ethyl-5-methylpyrrole-2-carboxylate) were prepared according to the method of A.W.Johnson et al, J. Chem. Soc., 4254 (1958).

N-Methylation of Pyrroles - General Procedure

A mixture of the pyrrole (20 mmol) methyl iodide (50 mmol) and potassium carbonate (50 mmol) was heated to reflux in methyl ethyl ketone (50 ml) for 8 h. If TLC (toluene/ethyl acetate 3:1) indicated incomplete reaction, further aliquots of methyl iodide (50 mmol) and potassium carbonate (50 mmol) were added and the mixture heated to reflux for a further 6 h. After evaporation in vacuo to dryness, the residue was taken up in warm water and extracted with ethyl acetate (3x50 ml). The combined extracts were dried over magnesium sulphate and evaporated in vacuo to leave a yellow oil or solid which was crystallised from aqueous ethanol.

Ethyl 4-acetyl-1,3,5-trimethylpyrrole-2-carboxylate

Obtained from ethyl 4-acetyl-3,5-dimethylpyrrole-2-carboxylate as white crystals (2g; 41%) m.p. 61-62°C (Found: C, 64.17; H, 7.82; N 6.16 $C_{12}H_{17}NO_3$ requires C, 64.55; H, 7.68; N, 6.27%) $\delta_H([^2H_6]-DMSO)$ 4.25 (2H, q, CH_2CH_3), 3.70 (3H, s, $1-CH_3$), 2.43 and 2.42 (2 x 3H, 2 x s, $3-CH_3$ and $COCH_3$), 2.38 (3H, s, $5-CH_3$) and 1.29 (3H, t, CH_2CH_3); m/z (%) 224(MH^+ , 100), 208(40), 194(20), 178(40) and 133(20)(FAB); ν_{max} (KBr Disc)/ CM^{-1} 2984, 1691 and 1651.

Benzyl 4-acetyl-1,3,5-trimethylpyrrole-2-carboxylate

Obtained from benzyl 4-acetyl-3,5-dimethyl-2-carboxylate as white crystals m.p. 78-79°C (Found: C, 71.30; H, 6.74; N, 4.79; $C_{17}H_{19}NO_3$ requires C, 71.56; H, 6.71; N, 4.91%); δ_H ($[^2H_6]$ -DMSO) 7.52-7.27 (5H, m, ArH), 5.30 (2H, s, CH_2 Ph), 3.73 (3H, s, 1- CH_3), 2.42 (6H, s, 3- CH_3 and COCH₃) and 2.38 (3H, s, 5- CH_3); m/z (%) 285(76, M^+), 270(87), 194(53), 178(23), 151(36), 136(26) and 91(100); ν_{max} (KBr Disc)/cm⁻¹ 2974, 1693 and 1641.

Preparation of the 5-Acetoxymethyl-4-acetylpyrroles - General procedure.

To a cooled (0°C) and stirred suspension of the 4-acetyl-5-methylpyrrole (0.02 mol) in dry diethyl ether (20 cm³) was added, dropwise over 15 min, freshly distilled sulfuryl chloride (2.2 cm³, 1.25 equiv.). The reaction mixture was stirred further and the chloromethyl derivative crystallised out slowly, filtration gave the 5-chloromethyl derivative as colourless crystals. The purity of the chloromethylpyrrole was checked by ¹H NMR spectroscopy (90 MHz) and it was used directly without recrystallisation.

The above chloromethylpyrrole (0.01 mol) was added to a solution of sodium acetate (3 g) in acetic acid (50 cm³), the mixture stirred for 2 h and poured into ice-water (200 cm³). The resulting solid was washed well with water until acid-free before drying.

Ethyl 5-acetoxymethyl-4-acetyl-3-methylpyrrole-2-carboxylate

crystallised from benzene as colourless needles (1.87 g, 70%) m.p. 135.5-138°C (Found: C, 58.6; H, 6.45; N, 5.15. $C_{13}H_{17}NO_5$ requires C, 58.4; H, 6.41; N, 5.24%); δ_H (CDCl₃) 9.57 (1 H, br s, NH), 5.40 (2 H, s, CH_2 OAc), 4.35 (2 H, q, OCH₂CH₃), 2.6 (3H, s, 3- CH_3) 2.5 (3 H, s,

COCH_3), 2.17 (3H, s, OCOCH_3) and 1.4 (3H, t, OCH_2CH_3); m/z (%) 267(83, M^+), 224(46), 207(27), 178(100) and 162(42).

Benzyl 5-acetoxymethyl-4-acetyl-3-methylpyrrole-2-carboxylate

crystallised from methanol as colourless needles (2.34 g, 71%) m.p. 138-141 °C (Found: C, 65.8; H, 5.95; N, 4.3 $\text{C}_{18}\text{H}_{19}\text{NO}_5$ requires C, 65.64; H, 5.81; N, 4.25%); δ_{H} (CDCl_3) 9.44 (1 H, br s NH), 7.49-7.32 (5 H, m, ArH), 5.40 (2H, s, CH_2OAc), 5.35 (2H, s, CH_2Ph), 2.62 (3H, s, 3- CH_3), 2.49 (3H, s, CH_3CO) and 2.14 (3H, s, OCOCH_3); m/z (%) 329 (9, M^+), 286 (13), 269(4), 178(19) and 91(100).

In the case of benzyl 5-acetoxymethyl-4-acetyl-3-(2-methoxycarbonyl-ethyl)-pyrrole-2-carboxylate, there was no precipitation when the solution was poured into ice-water. Extraction with chloroform (3 x 100 cm^3), drying and removal of solvent under reduced pressure gave an oil which was crystallised from benzene-light petroleum to yield colourless needles (2.69g, 67%) m.p. 97-100 °C (Found C, 62.9; H 5.9; N 3.45. $\text{C}_{21}\text{H}_{23}\text{NO}_7$ requires C, 62.8; H, 5.78; N, 3.49%); δ_{H} (CDCl_3) 9.15 (1H, br s, NH), 7.50-7.30 (5H, m, ArH), 5.35 (4 H, s, CH_2Ph and CH_2OAc), 3.63 (3 H, s, OCH_3), 3.37 (2 H, t, $\text{CH}_2\text{CH}_2\text{CO}$), 2.58 (2 H, t, CH_2CO), 2.51 (3 H, s, COCH_3) and 2.15 (3 H, s, OCOCH_3); m/z (%) 401(4, M^+), 341(8), 268(6), 250(60) and 91(100).

Ethyl 5-acetoxymethyl-4-acetyl-1,3-dimethylpyrrole-2-carboxylate

Crystallised from ethyl acetate/cyclohexane (61%) m.p. 100-101 °C. (Found: C, 59.38; H, 6.73; N, 4.95. $\text{C}_{14}\text{H}_{19}\text{NO}_5$ requires C, 59.78; H, 6.81; N, 4.98%); δ_{H} ($[\text{}^2\text{H}_6\text{]}\text{-DMSO}$) 5.30 (2H, s, CH_2OAc), 4.29 (2H, q, CH_2CH_3), 3.77 (3H, s, N- CH_3), 2.43 and 2.42 (2 x 3H, 2 x s, 3- CH_3 and CH_3CO), 2.02 (3H, s, OCOCH_3) and 1.31 (3H, t, CH_2CH_3); m/z (%) 281 (34, M^+), 238(100), 222(48) and 192(52); ν_{max} (KBr Disc)/ cm^{-1} 1712 and 1697.

Benzyl 5-acetoxymethyl-4-acetyl-1,3-dimethylpyrrole-2-carboxylate

Crystallised from ethyl acetate/cyclohexane. δ_H ($^2[H]_6$ -DMSO) 7.51-7.32 (5H, m, ArH), 5.34 and 5.32 (2 x 2H, 2 x s, CH_2Ph and CH_2OAc), 3.78 (3H, s, $N-CH_3$), 2.46 and 2.45 (2 x 3H, 2 x s, $3-CH_3$ and CH_3CO) and 2.04 (3H, s, $OCOCH_3$); m/z (%) 343(5, M^+), 284(100) and 91(95).

Ethyl 5-acetoxymethyl-4-acetyl-3-ethylpyrrole-2-carboxylate

Crystallised from ether/petrol as fawn needles (61%) with m.p. 97-98°C (Found: C, 59.44; H, 6.78; N, 4.80. $C_{14}H_{19}NO_5$ requires: C, 59.76; H, 6.81; N, 4.98%); δ_H ($CDCl_3$) 9.40 (1H, br s, 1-NH), 5.38 (2H, s, CH_2OAc), 4.38 (2H, q, J 7, CO_2CH_2), 3.10 (2H, q, J 7.5, $3-CH_2$), 2.54 (3H, s, $COCH_3$), 2.18 (3H, s, $OCOCH_3$), 1.40 (3H, t, J 7.5, $CO_2CH_2CH_3$), 1.23 (3H, t, J 7.5, $3-CH_2CH_3$); m/z (%) 281 (42, M^+), 238(61), 221(89), 206(58), 192(92), 175(95), 160(81), 147(59), 43(100); ν_{max} (KBr disc)/ cm^{-1} 3277, 1738, 1674, 1657.

Synthesis of the 3-(Pyrrolylmethyl)indole, 2-(Pyrrolylmethyl)benzofuran and 3-(Pyrrolylmethyl)benzothiophene - General procedure.

A solution of the 5-acetoxymethyl-4-acetylpyrrole (1.0 mmol) and indole (1.0 mmol) in 1,2-dichloroethane (10 cm^3) was heated at gentle reflux and stirred with Montmorillonite clay (1 g) for 1.5-2 h. After filtration from clay and washing well with 1,2-dichloroethane, evaporation of the combined filtrates under reduced pressure gave an oil. This oil was submitted to flash chromatography on silica, eluting with ethyl acetate in light petroleum to give 3-(3'-acetyl-5'-ethoxycarbonyl-4'-methylpyrrol-2'-ylmethyl)indole. It gave colourless crystals from ethyl acetate-light petroleum (0.1465 g, 45%). m.p. 180-182°C (Found: C, 70.5; H, 6.25; N, 8.65. $C_{19}H_{20}N_2O_3$ requires C, 70.4; H, 6.21; N, 8.64%); δ_H ($CDCl_3$) 8.78 (1H, s, pyr-NH), 8.27 (1 H, s, ind-NH), 7.45 (1H, d, J7, 4-H) 7.42 (1H, d, J7, 7-H), 7.25 (1H, t, J7, 6-H), 7.14 (1H, t, J7, 5-H), 7.10 (1H, s, 2-H), 4.45 (2H, s, $3-CH_2$), 4.22 (2H, q, OCH_2CH_3), 2.63 (3H, s, $4'-CH_3$) 2.53 (3H, s, CH_3CO) and 1.25 (3 H, t, OCH_2CH_3); m/z (%) 324(100, M^+) 309(48),

277(25), 263(54), 250(38), 235(30), 207(48), 139(24), 130(30), 117(67) and 90(16); $\nu_{\max}(\text{CHCl}_3)/\text{cm}^{-1}$ 3490, 3430, 1680 and 1650.

Benzofuran (1.0 mmol) when used instead of indole, after chromatography, gave 2-(3'-acetyl-5'-ethoxycarbonyl-4'-methylpyrrol-2'-ylmethyl)benzofuran (0.106 g, 32.6%), m.p. 124-127°C (Found: C, 70.1; H, 6.1; N, 4.15 $\text{C}_{19}\text{H}_{19}\text{NO}_4$ requires C, 70.14; H, 5.89; N, 4.31%); $\delta_{\text{H}}(\text{CDCl}_3)$ 9.25 (1 H, s, NH), 7.50 (1 H, d, J7.3, 4-H), 7.44 (1H, d, J7.3, 7-H), 7.28-7.18 (2 H, m, 6-H and 5-H), 6.57 (1 H, s, 3-H), 4.50 (2 H, s, 2-CH₂), 4.31 (2 H, q, OCH₂CH₃) 2.62 (3 H, s, 4'-CH₃) 2.50 (3 H, s, CH₃CO) and 1.35 (3 H, t, OCH₂CH₃); saturation of the singlet 3-H at δ 6.51 enhanced the signals due to 4H at δ 7.50 (2.7%) and 2-CH₂ at δ 4.50 (0.8%); m/z (%) 325(100, M⁺), 310(4), 279(29), 264(17), 251(59), 236(27), 208(19), 193(9), 131(7) and 118(7); and the 2,3-bis (3'-acetyl-5'-ethoxycarbonyl-4'-methylpyrrol-2'-ylmethyl)benzofuran (0.0238 g, 8.94%) m.p. 255-257°C; $\delta_{\text{H}}(\text{CDCl}_3)$ 10.09 (1 H, s, NH) 9.95 (1H, s, NH), 7.32 (1H, d, J7.7, 4-H), 7.27 (1 H, d, J7.7, 7-H), 7.17 (1 H, t, J7.7, 6-H), 7.08 (1 H, t, J7.7, 5-H) 4.45 (2 H, s, 2-CH₂), 4.40 (2 H, s, 3-CH₂), 4.36 (2H, q, OCH₂CH₃), 4.27 (2 H, q, OCH₂CH₃), 2.64 (3 H, s, 4'-CH₃), 2.63 (3H, s, 4'-CH₃), 2.58 (3H, s, CH₃CO), 2.54 (3 H, s, CH₃CO), 1.39 (3H, t, OCH₂CH₃) and 1.31 (3 H, t, OCH₂CH₃); m/z (%) 532(11, M⁺), 490(24), 444(9), 397(6), 324(100), 282(18), 278(27), 236(20), 209(28) and 162(28) (Found: M⁺, 532.2210. $\text{C}_{30}\text{H}_{32}\text{N}_2\text{O}_7$ requires M, 532.2209).

When benzothiophene (1.0 mmol) was used in the same way as indole, chromatography using ethyl acetate in dichloromethane as eluent gave colourless crystals of 3-(3'-acetyl-5'-ethoxycarbonyl-4'-methylpyrrol-2'-ylmethyl)benzothiophene (0.0963g, 28.2%) m.p. 125-128°C (Found: C, 66.75; H, 5.8; N, 4.1 $\text{C}_{19}\text{H}_{19}\text{NO}_3\text{S}$ requires C, 66.84; H, 5.61; N, 4.10%); $\delta_{\text{H}}(\text{CDCl}_3)$ 8.72 (1 H, br, s, NH), 7.88 (1 H, m, 4-H), 7.63 (1 H, m, 7-H), 7.37 (2 H, m, 6-H and 5-H), 7.20 (1 H, s, 2-H), 4.54 (2 H, s, 3-CH₂), 4.23 (2 H, q, OCH₂CH₃), 2.62 (3 H, s, 4'-CH₃), 2.53 (3 H, s, CH₃CO) and 1.28 (3 H, t, OCH₂CH₃); saturation of the 3-CH₂ protons at δ 4.54 enhanced the signals due to NH at δ 8.72 (3.3%), 4-H

at δ 7.88 (7.7%), 2-H at δ 7.20(6%) and CH_3CO at δ 2.53 (1.3%); m/z (%) 341(100, M^+), 326(9), 298(6), 295(20), 230(39), 267(46), 252(32), 224(27), 194(26) and 148(22); and the 2,3-bis (3'-acetyl-5'-ethoxycarbonyl-4'-methylpyrrol-2'-ylmethyl)benzothiophene as a pale yellow solid (0.0264 g, 9.6%), m.p. 206-209°C (Found: C, 65.6; H, 5.8; N 5.1 $\text{C}_{30}\text{H}_{32}\text{N}_2\text{O}_6\text{S}$ requires C, 65.67; H, 5.88; N, 5.11%), δ_{H} (CDCl_3) 9.77 (1H, br, s, NH), 9.43 (1H, br, s, NH), 7.70 (1 H, m, 4-H), 7.49(1 H, m, 7-H), 7.26 (2 H, m, 6-H and 5-H), 4.55 (2 H, s, CH_2), 4.53(2 H, s, CH_2), 4.32 (2 H, q, OCH_2CH_3), 4.24 (2 H, q, OCH_2CH_3), 2.61 (3 H, s, 4'- CH_3), 2.60 (3 H, s, 4'- CH_3), 2.57 (3H, s, CH_3CO) 2.49 (3 H, s, CH_3CO), 1.35 (3H,t, OCH_2CH_3) and 1.28 (3H H,t, OCH_2CH_3); m/z (%) 548(5, M^+), 530(11), 340(100), 294(27) and 162(10).

Example 2

Synthesis of 3-(Pyrrolylmethyl)benzothiophenes and 3-(Pyrrolylmethyl)indoles

a) 3-(3'-Acetyl-5'-benzyloxycarbonyl-4'-methylpyrrol-2'-ylmethyl)benzothiophene

A solution of the 5-acetoxymethyl-4-acetylpyrrole (0.33g; 1.0 mmol) and benzothiophene (0.14 g; 1.05 mmol) in 1,2-dichloroethane (10 cm^3) was heated at reflux and stirred with Montmorillonite K10 clay (1 g) for 2.5 h. After cooling and filtration from the clay, which was washed well with 1,2-dichloroethane, the combined filtrates were evaporated under reduced pressure to leave a yellow oil. Flash chromatography on silica, eluting with diethyl ether/light petroleum (1:2) gave the title compound as a colourless solid.

δ_{H} (CDCl_3) 8.72 (1H, s, NH), 7.92-7.84 (1H, m, 4-H), 7.69-7.58 (1H, m, 7-H), 7.43-7.16 (8H, m, 2-H, 5-H, 6-H, ArH), 5.23 (2H, s, CH_2Ph), 4.50 (2H, s, 3- CH_2), 2.61 (3H, s, 4'- CH_3) and 2.50

(3H, s, CH_3CO); m/z (%) 403 (M^+ , 100); ν_{max} (KBr Disc)/ cm^{-1} 3290, 1690 and 1659.

b). 3-(3'-Acetyl-5'-ethoxycarbonyl-4'-methylpyrrol-2'-ylmethyl)-5-cyanoindole

A solution of the 5-acetoxymethyl-4-acetylpyrrole (0.7 g, 2.6 mmol) and 5-cyanoindole (0.41 g, 2.9 mmol) in 1,2-dichloroethane (50 cm^3) was heated at reflux and stirred with Montmorillonite K10 clay (2.1 g) for 6 h. After cooling and filtration from the clay, which was washed well with 1,2-dichloroethane, the combined filtrates were evaporated under reduced pressure to leave an orange solid. Crystallisation from dichloromethane/ethyl acetate yielded a small amount of analytically pure title compound as cream crystals. The evaporated mother liquors were submitted to flash chromatography on silica, eluting with dichloromethane/ethyl acetate (9:1) to give further product (0.65g, 71%). m.p. 213-214°C (Found: C, 68.60; H, 5.46; N, 11.99. $\text{C}_{20}\text{H}_{19}\text{N}_3\text{O}_3$ requires C, 68.75; H, 5.48; N, 12.03%) δ_{H} ($[\text{}^2\text{H}_6]$ -DMSO) 12.05 (1H, s, 1'-NH), 11.38 (1H, s, 1-NH), 8.20 (1H, m, 4-H), 7.50 (1H, dd, J0.7 and 8.5, 7-H), 7.39 (1H, dd, J1.7 and 8.5, 6-H), 7.18 (1H, s, 2-H), 4.32 (2H, s, 3- CH_2 4.27 (2H, q, CH_2CH_3), 2.33 (3H, s, 4'- CH_3), 2.51 (3H, s, CH_3CO) and 1.30 (3H, t, CH_2CH_3); m/z (%) 350 (M^+ , 70), 302(16), 279(18), 237(35), 208(100) and 181(20); ν_{max} (KBr Disc)/ cm^{-1} 3309, 2218 and 1665.

c). 3-(3'-Acetyl-5'-ethoxycarbonyl-4'-methylpyrrol-2'-ylmethyl) indole-5-carboxylic acid

A solution of the 5-acetoxymethyl-4-acetylpyrrole (0.74g, 2.8 mmol) and indole-5-carboxylic acid (0.5g, 3 mmol) in toluene (50 cm^3) was stirred at room temperature with Montmorillonite K10 clay (1 g) for 10 days. After cooling and filtration from the clay, which was washed well with toluene, the combined filtrates

were evaporated under reduced pressure to leave an orange solid. Crystallisation from ethyl acetate/cyclohexane yielded the title compound as a grey powder (0.15g, 15%). m.p. 227-228°C (Found: C, 64.96; H, 5.58; N, 7.34. $C_{20}H_{20}N_2O_5$ requires C, 65.21; H, 5.47; N, 7.60%); $\delta_H([^2H_6]-DMSO)$ 12.35 (1H, br, CO_2H) 12.04 (1H, s, 1'-NH), 11.17 (1H, s, 1-NH), 8.31 (1H, d, J1.6, 4-H), 7.70 (1H, dd, J1.6 and 8.7, 6-H), 7.37 (1H, d, J8.7, 7-H), 6.98 (1H, s, 2-H), 4.36 (2H, s, 3- CH_2), 4.26 (2H, q, CH_2CH_3), 2.51 and 2.31 (2 x 3H, 2 x s, 4'- CH_3 and CH_3CO) and 1.29 (3H, t, CH_2CH_3); m/z (%) 369(22($M+1$)⁺), 351(37), 323(18), 305(19), 232(19), 208(60) and 181(20), 162(100); ν_{max} (KBr Disc)/cm⁻¹ 3359 and 1676.

d) 3-(3'-Acetyl-5'-ethoxycarbonyl-4'-methylpyrrol-2'-ylmethyl)-5-bromoindole

A solution of the 5-acetoxymethyl-4-acetylpyrrole (1.3g, 4.9 mmol) and 5-bromoindole (1.09g, 5.6 mmol) in 1,2-dichloroethane (100 cm³) was heated at reflux and stirred with Montmorillonite K10 clay (3 g) for 5 h. After cooling and filtration from the clay, which was washed well with 1,2-dichloroethane, the combined filtrates were evaporated under reduced pressure to leave a yellow solid. Crystallisation from dichloromethane/light petroleum/acetone yielded the title compound as cream crystals (0.33 g, 17%). m.p. 181-183°C (Found: C, 56.24; H, 4.70; N, 6.86. $C_{19}H_{19}BrN_2O_3$ requires C, 56.59; H, 4.75; N, 6.95%); $\delta_H([^2H_6]-DMSO)$ 12.00 (1H, s, 1'-NH), 11.00 (1H, s, 1-NH), 7.82 (1H, d, J1.9, 4-H), 7.31 (1H, d, J8.6, 7-H), 7.16 (1H, dd, J1.9 and 8.6, 6-H), 7.02 (1H, s, 2-H), 4.30 (2H, s, 3- CH_2), 4.28 (2H, q, CH_2CH_3), 2.51 and 2.33 (2 x 3H, 2 x s, 4'- CH_3 and CH_3CO) 1.31 (3H, t, CH_2CH_3) m/z (%) 404 and 402(100 M^+), 389 and 387(24), 357(24), 330 and 328(32), 206(36) and 178(26); ν_{max} (KBr Disc)/cm⁻¹ 3373 and 1672.

Example 3a) Ethyl 3,4-dimethylpyrrolo[3,2,-b]carbazole-2-carboxylate

A solution of the 3-(pyrrolylmethyl)indole (0.108 g 0.33 mmol) was heated at gentle reflux in 1,2-dichloroethane (10 cm³) and stirred with Montmorillonite K10 clay (1 g) for 2 h. TLC then showed a single compound had been formed and that reaction was complete. After filtration from clay and washing well with 1,2-dichloroethane, evaporation of the combined filtrates under reduced pressure gave a yellow solid which crystallised from ethyl acetate to give the pyrrolo[3,2-b]-carbazole as yellow crystals (0.076 g; 75%), m.p. 209.5-211°C (Found: C, 74.6; H, 6.14; N, 9.03. C₁₉H₁₈N₂O₂ requires C, 74.5; H, 5.92; N, 9.14%); $\delta_{\text{H}} [^2\text{H}_6] \text{-DMSO}$) 11.22 (1H, s, 1-NH), 10.70 (1 H, s, 5-NH), 8.06 (1H, d, J7, 9-H), 7.85 (1H, s, 10-H), 7.40 (1H, d, J7, 6-H), 7.35 (1H, t, J7, 7-H), 7.08 (1H, t, J7, 8-H), 4.35 (2H, q, OCH₂CH₃) 2.91 and 2.90 (2 x 3H, 2 x s, 3-CH₃ and 4-CH₃ and 1.35 (3 H, t, OCH₂CH₃). Saturation of the 10-H at δ 7.85 enhanced the singlets due to 1-NH at δ 11.22 (3%) and 9-H at δ 8.06 (4%); m/z(%) 306(56, M⁺), 260(100), 323(39), 205(15), 140(18) and 130(26); $\nu_{\text{max}} (\text{CHCl}_3) / \text{cm}^{-1}$ 3480 and 1700; $\lambda_{\text{max}} (\text{EtOH}) / \text{nm}$ 226, 268, 310sh, 327sh, 340, 390 and 410sh.

b) Ethyl 3,4-dimethyl-1H-benzofuro[3,2,-f]indole-2-carboxylate

Toluene-p-sulfonic acid (50 mg) was added to a solution of the 2-(pyrrolylmethyl)benzofuran (0.100 g 0.31 mmol) in toluene (10 cm³), and the reaction mixture was heated under reflux for 3 h. On cooling, the product crystallised out, and after filtration and washing with ethanol gave the title compound as pale yellow crystals (0.084 g, 88.8%), m.p. 262-265°C (Found: C, 74.25; H, 5.55; N, 4.6 C₁₉H₁₇NO₃ requires C, 74.25; H, 5.56; N, 4.56%);

$\delta_{\text{H}}([^2\text{H}_6]\text{-DMSO})$ 11.52 (1 H, s, 1-NH), 8.18 (1 H, d, J7.5, 5-H), 7.62 (1 H, d, J7.5, 8-H), 7.46 (1 H, t, J7.5, 7-H), 7.38 (1H, t, J7.5, 6-H) 7.38 (1 H, s, 10-H), 4.37 (2 H, q, OCH_2CH_3), 3.14 (3 H, s, 4- CH_3), 2.91 (3 H, s, 3- CH_3) and 1.39 (3 H, t, OCH_2CH_3); saturation of the 4- CH_3 at δ 3.14 enhanced the signals due to 5-H at δ 8.18 (4.5%) and 3- CH_3 at δ 2.91 (2.6%); m/z (%) 307 (53, M^+), 261(100), 233(31) and 205(9); ν_{max} (Nujol)/ cm^{-1} 3350 and 1686; λ_{max} (EtOH)/nm 240, 269, 293, 330 and 344.

c) Ethyl 3,4-dimethyl-1H-[1]benzothieno[2,3-f]indole-2-carboxylate

Toluene-p-sulfonic acid (45 mg) was added to the solution of the 3-(pyrrolylmethyl)benzothiophene (0.100 g, 0.29 mmol) in toluene (10 cm^3) and the reaction mixture was heated under reflux for 3 h. Evaporation of the solvent and washing the resulting solid with ethanol gave the title compound as a pale yellow solid (0.0758 g, 80%), m.p. 191-193 $^{\circ}\text{C}$ (Found: C, 70.3; H 5.5; N, 4.2. $\text{C}_{19}\text{H}_{17}\text{NO}_2\text{S}$ requires C, 70.6; H, 5.30; N, 4.33%); $\delta_{\text{H}}([^2\text{H}_6]\text{-DMSO})$ 11.64 (1 H, s, NH), 8.25 (1 H, m, 9-H), 8.12 (1 H, s, 10-H) 7.95 (1 H, m, 6-H), 7.48 (2 H, m, 7-H and 8-H), 4.38 (2 H, q, OCH_2CH_3), 2.87 and 2.85 (2 x 3H, 2 x s, 3- CH_3) and 1.37 (3 H, t, OCH_2CH_3); m/z (%) 323(53, M^+), 277(100), 249(33), 221(15), 139(7) and 111(11); ν_{max} (Nujol)/ cm^{-1} 3350 and 1686; λ_{max} (EtOH)/ nm 240, 269, 293, 330 and 344.

d) Benzyl 3,4-dimethyl-1H-[1]benzothieno[2,3-f]indole-2-carboxylate

Toluene-p-sulphonic acid (40 mg) was added to the solution of the 3-(pyrrolylmethyl)benzothiophene (0.100 g, 0.25 mmol) in toluene (12 cm^3) and the reaction heated under reflux for 6 h. Evaporation of the solvent and washing the resultant solid with ethanol gave the title compound as a pale yellow solid (0.02 g, 20%) m.p. 203-204 $^{\circ}\text{C}$ (Found: C, 74.7; H, 4.9; N, 3.6; $\text{C}_{24}\text{H}_{19}\text{NO}_2\text{S}$ requires C, 74.8; H, 5.0; N, 3.6%); $\delta_{\text{H}}([^2\text{H}_6]\text{-DMSO})$ 11.64 (1H,

s, NH) 8.27-8.15 (1H, m, 9-H), 8.10 (1H, s, 10-H), 7.90-7.89 (1H, m, 6-H). 7.60-7.30 (7H, m, 7-H, 8-H, ArH), 5.40 (2H, s, CH₂) and 2.87 (6H, s, 2 x CH₃); m/z (%) 385(100, M⁺), 277(89), 248(25), 221(15) and 91(28); ν_{\max} (KBr Disc/cm⁻¹) 3331 and 1672.

e) Ethyl 8-cyano-3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

A mixture of the 3-(pyrrolylmethyl)indole (0.6 g, 1.7 mmol) and Montmorillonite K10 clay (2 g) in toluene was stirred and heated at reflux for 24 h. After cooling and filtration from the clay, which was washed well with toluene, the combined filtrates were evaporated under reduced pressure to leave a brown solid which was submitted to flash chromatography on silica, eluting with cyclohexane/ethyl acetate (3:1) to give a yellow solid. Crystallisation from cyclohexane/ethyl acetate yielded the title compound as a yellow powder (0.030 g, 5%). m.p. >240°C (Found: C, 71.54; H, 5.18; N, 12.78, C₂₀H₁₇N₃O₂·0.2H₂O requires C, 71.71; H, 5.24; N, 12.54%) δ_{H} ([²H₆]-DMSO) 11.39 (1H, s, 1-NH), 11.29 (1H, s, 5-NH), 8.65 (1H, d, J1.7, 9-H), 8.01 (1H, s, 10-H), 7.71 (1H, dd, J1.7 and 8.6, 7-H), 7.50 (1H, d, J8.6, 6-H), 4.36 (2H, q, CH₂CH₃), 2.91 and 2.89 (2 x 3H, 2 x s, 4-CH₃ and 3-CH₃) and 1.38 (3H, t, CH₂CH₃); m/z (%) 331 (52, M⁺), 285(100), 256(32), 229(12), 167(14) and 149(40); ν_{\max} (KBr Disc)/cm⁻¹ 3414, 3550, 2212 and 1664.

f) 3,4-Dimethyl-2-ethoxycarbonylpyrrolo[3,2-b]carbazole-8-carboxylic acid

A mixture of the 3-(pyrrolylmethyl)indole (0.1g, 0.3 mmol) and Montmorillonite K10 clay (0.34 g) in toluene (15 cm³) was stirred and heated at reflux for 6 h. After cooling and filtration from the clay, which was washed well with toluene, the combined filtrates were evaporated under reduced pressure to leave an orange solid. Crystallisation from methanol/dichloromethane yielded the title compound as a yellow powder (0.027 g,

28%). m.p. $>260^{\circ}\text{C}$ (Found: C, 68.12; H, 5.19; N, 7.91 $\text{C}_{20}\text{H}_{18}\text{N}_2\text{O}_4 \cdot 0.05\text{H}_2\text{O}$ requires C, 68.39; H, 5.19; N, 7.98%); δ_{H} ($^2\text{H}_6$ -DMSO) 12.42 (1H, br, COOH), 11.30 (1H, s, 1-NH), 11.09 (1H, s, 5-NH), 8.68 (1H, s, 10-H), 8.07-7.93 (2H, m, 7-H and 9-H), 7.45 (1H, d, J9, 6-H), 4.38 (2H, q, CH_2CH_3), 2.94 and 2.90 (2 x 3H, 2 x s, 4- CH_3 and 3- CH_3) and 1.39 (3H, t, CH_2CH_3); m/z (%) 350(100, M^+), 304(100), 278(40), 232(35) and 181(38); ν_{max} (KBr Disc)/ cm^{-1} 3459, 1697 and 1674.

g) Ethyl 8-bromo-3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

A mixture of the 3-(pyrrolylmethyl)indole (0.3g, 0.74 mmol) and Montmorillonite K10 clay (1 g) in toluene was stirred and heated at reflux for 6 h. After cooling and filtration from the clay, which was washed well with toluene, the combined filtrates were evaporated under reduced pressure to leave a brown solid which was submitted to flash chromatography on silica, eluting with dichloromethane/light petroleum (7:3) to give a yellow solid. Crystallisation from cyclohexane/ethyl acetate yielded the title compound as a yellow powder (0.070 g, 24%). m.p. $204-205^{\circ}\text{C}$ (decomp.) (Found: C, 59.17; H, 4.43; N, 7.30. $\text{C}_{19}\text{H}_{17}\text{BrN}_2\text{O}_2$ requires C, 59.23; H, 4.45; N, 7.27%); δ_{H} ($^2\text{H}_6$ -DMSO) 11.26 (1H, s, 1-NH), 10.79 (1H, s, 5-NH), 8.30 (1H, d, J2.2, 9-H), 7.92 (1H, s, 10-H), 7.47 (1H, dd, J2.2 and 8.8, 7-H), 7.35 (1H, d, J8.8, 6-H), 4.36 (2H, q, CH_2CH_3), 2.89 and 2.88 (2 x 3H, 2 x s, 4- CH_3 and 3- CH_3) and 1.38 (3H, t, CH_2CH_3); m/z (%) 386 and 384(100, M^+), 340 and 338(70), 232(60) and 181(50); ν_{max} (KBr Disc)/ cm^{-1} 3350, 1705 and 1663.

Example 4One-pot Synthesis of the Pyrrolocarbazoles - General procedure.

A solution of indole (1.0 mmol) and the 5-acetoxymethyl-4-acetylpyrrole (1.0 mmol) in 1,2-dichloroethane (10 cm³) was heated under gentle reflux and stirred with Montmorillonite K10 clay (1 g) for 3-4 h. The colour of clay turned light brown and the reaction was followed to completion by TLC. After filtration from clay and washing well with 1,2-dichloroethane, evaporation of the combined filtrates gave the pyrrolo[3,2-b]carbazoles which were obtained as yellow crystals after crystallisation from dichloromethane or ethyl acetate.

a) Ethyl 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.199 g, 65%) was obtained from the reaction of indole and the 5-acetoxymethyl-4-acetylpyrrole. It was identical in all respects to the pyrrolo[3,2-b]carbazole from example 1.

b) Benzyl 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.179 g, 48.8%) was obtained from the reaction between indole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 229-232°C (Found: C, 78.2; H, 5.65; N, 7.8. C₂₄H₂₀N₂O₂ requires C, 78.23; H, 5.47; N, 7.60%); $\delta_{\text{H}} [^2\text{H}_6] \text{-DMSO-}d_6$) 11.29 (1 H, s, 1-NH), 10.65 (1 H, s, 5-NH), 8.08 (1 H, d, J8, 9-H), 7.89 (1 H, s, 10-H), 7.56-7.34 (7 H, m, ArH, 6-H and 7-H), 7.08 (1 H, t, J7, 8-H), 5.42 (2 H, s, CH₂Ph) and 2.92 (6H, s, 3-CH₃ and 4-CH₃); m/z (%) 368(74, M⁺), 354(10), 260(100), 246(13), 231(20) and 91(31).

The pyrrolo[3,2-b]carbazole (0.166 g, 45%) was also obtained from the reaction of indole and the 4-acetyl-5-(ethoxymethyl)-pyrrole.

c) Ethyl 8-methoxy-3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

Was obtained from the reaction of 5-methoxyindole and the 5-acetoxymethyl-4-acetyl pyrrole, it had m.p. 119-122°C (Found: C, 71.6; H, 6.0; N, 8.05. $C_{20}H_{20}N_2O_3$ requires C, 71.4; H, 5.99; N, 8.33%); δ_H ($[^2H_6]$ -DMSO) 11.20 (1 H, s, 1-NH), 10.38 (1 H, s, 5-NH), 7.85 (1 H, s, 10-H), 7.62 (1 H, d, J 2.5, 9-H), 7.31 (1 H, d, J9, 6-H), 7.01 (1 H, dd, J9 and 2.5, 7-H), 4.38 (2 H, q, OCH_2CH_3), 3.88 (3 H, s, OCH_3), 2.89 and 2.87 (2 x 3H, 2 x S, 3- CH_3 and 4- CH_3) and 1.39 (3 H, t, OCH_2CH_3); m/z (%) 336(60, M^+), 290(100), 275(5), 262(4), 247(23), 219(8) and 145(9).

d) Benzyl 8-methoxy-3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.139 g, 35%) was obtained from the reaction of 5-methoxy indole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 212-215°C (Found: C, 75.4; H, 5.55; N, 6.95. $C_{25}H_{22}N_2O_3$ requires C, 75.4; H, 5.57; N, 7.03%); δ_H ($[^2H_6]$ -DMSO) 11.29 (1 H, s, 1-NH), 10.38 (1H, s, 5-NH), 7.88 (1 H, s, 10-H), 7.65 (1 H, d, J2.5, 9-H), 7.58-7.36 (5H, m, ArH), 7.32 (1H, d, J9, 6-H), 7.02 (1 H, dd, J9 and 2.5, 7-H), 5.43 (2 H, s, CH_2Ph), 3.88 (3 H, s, OCH_3), 2.92 (3 H, s, 4- CH_3) and 2.89 (3H, s, 3- CH_3); m/z (%) 398(73, M^+), 290(100), 262(10), 247(15), 219(7) and 91(17).

e) Ethyl 8-fluoro-3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.131 g, 40.5%) was obtained from the reaction of 5-fluoro-indole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 231-234°C (Found: C, 70.5; H, 5.3; N, 8.4. $C_{19}H_{17}FN_2O_2$ requires C, 70.4; H, 5.28; N, 8.64%); δ_H ($[^2H_6]$ -DMSO) 11.27 (1 H, s, 1-NH), 10.64 (1H, s, 5-NH), 7.93 (1 H, dd, J9 and 2.5, 9-H), 7.88 (1 H, s, 10-H), 7.36 (1 H, dd, J9 and 6,6-H), 7.19 (1 H, dt, J9 and 2.5, 7-H), 4.36 (2 H, q, OCH_2CH_3), 2.88 (6 H, s, 3- CH_3 and

4-CH₃) and 1.37 (3 H, t, OCH₂CH₃); m/z (%) 324(50, M⁺) 278(100), 250(31), 220(10), 139(8), 125(7) and 111(8)

f) Benzyl 8-fluoro-3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.155 g, 40%) was obtained from 5-fluoroindole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 217-219°C (Found: C, 74.6; H, 4.95; N, 7.3. C₂₄H₁₉FN₂O₂ requires C, 74.6; H, 4.96; N, 7.25); δ_H(²H₆]-DMSO) 11.36 (1 H, s, 1-NH), 10.86 (1 H, s, 5-NH), 7.94 (1 H, dd, J₉ and 2.5, 9-H), 7.89 (1 H, s, 10-H), 7.56-7.38 (5 H, m, ArH), 7.39 (1 H, dd, J₉ and 4,6-H), 7.21 (1 H, dt, J₉ and 2.5, 7-H), 5.42 (2 H, s, CH₂Ph), 2.91 and 2.90 (2 x 3H, 2 x s, 3-CH₃ and 4-CH₃); m/z (%) 386(68, M⁺), 278(100), 249(22) and 91(43).

g) Ethyl 3,4,6-trimethylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.206 g, 64.4%) was obtained from the reaction of 7-methylindole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 230°C (decomp.) (Found: C, 74.9; H, 6.25; N, 8.65. C₂₀H₂₀N₂O₂ requires C, 75.0; H, 6.29; N, 8.74%); δ_H(²H₆]-DMSO) 11.20 (1 H, s, 1-NH), 10.11 (1 H, s, 5-NH), 7.89 (1 H, d, J_{7.5}, 9-H), 7.84 (1 H, s, 10-H), 7.18 (1 H, d, J_{7.5}, 7-H), 7.01 (1 H, t, J_{7.5}, 8-H), 4.37 (2 H, q, OCH₂CH₃), 2.98 (3 H, s, 4-CH₃), 2.91 (3 H, s, 3-CH₃), 2.58 (3 H, s, 6-CH₃) and 1.34 (3 H, t, OCH₂CH₃); m/z (%) 320(54, M⁺), 274(100), 246(30), 230(5), 137(9), 123(7) and 109(6).

h) Benzyl 3,4,6-trimethylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.167 g, 43.7%) was obtained from the reaction of 7-methylindole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 222°C (decomp.) (Found: C, 78.5; H, 5.9; N, 7.25. C₂₅H₂₂N₂O₂ requires C, 78.5; H, 5.80; N, 7.33%); δ_H(²H₆]-DMSO) 11.27 (1 H, s,

1-NH), 10.11 (1 H, s, 5-NH), 7.89 (1 H, d, J7, 9-H), 7.85 (1 H, s, 10-H), 7.56-7.35 (5 H, m, ArH), 7.18 (1H, d, J7, 7-H), 7.08 (1H, t, J, 8-H), 5.43 (2H, s, CH_2Ph), 2.99 (3H, s, 4- CH_3), 2.93 (3 H, s, 3- CH_3) and 2.59 (3 H, s, 6- CH_3); m/z (%) 382(71, M^+) 274(100), 246(19) and 91(22).

i) Benzyl 3-(2-methoxycarbonylethyl)-4-methylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.230 g, 52.3%) was obtained from indole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 211-213°C (Found: C, 73.7; H, 5.6; N, 6.2. $\text{C}_{27}\text{H}_{24}\text{N}_2\text{O}_4$ requires C, 73.6; H, 5.49; N, 6.36%); $\delta_{\text{H}}([{}^2\text{H}_6]-\text{DMSO})$ 11.51 (1 H, s, 1-NH), 10.71 (1 H, s, 5-NH), 8.75 (1 H, d, J7.5, 9-H), 7.92 (1 H, s, 10-H), 7.57-7.44 (7 H, m, ArH, 6-H and 7-H), 7.18 (1 H, t, J7.5, 8-H), 5.43 (2 H, s, CH_2Ph), 3.63 (3 H, s, OCH_3), 3.59 (2 H, partially obscured, t, $\text{CH}_2\text{CH}_2\text{CO}$), 2.88 (3 H, s, 4- CH_3) and 2.65 (2 H, t, CH_2CO); m/z (%) 440(100, M^+), 332(20), 290(47), and 91(57).

j) Ethyl 3,4,5-trimethylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.140 g, 16%) was obtained from the reaction (2.65 mmol scale) between N-methylindole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 208°C (decomp.) (Found: C, 75.12; H, 6.40; N, 8.69, $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_2$ requires C, 74.98; H, 6.29; N, 8.74%); $\delta_{\text{H}}([{}^2\text{H}_6]-\text{DMSO})$ 11.28 (1H, s, 1-NH), 8.08 (1H d, J7.9, 9-H), 7.88 (1H, s, 10-H), 7.44 (2 H, m, 6-H, 7-H), 7.07-7.17 (1 H, m, 8-H), 4.36 (2 H, q, CH_2CH_3), 4.01 (3H, s, 5- CH_3), 3.13 (3H, s, 4- CH_3), 2.90 (3H, s, 3- CH_3), and 1.38 (3H, t, CH_2CH_3); m/z (%) 320(72, M^+), 274(100), 245(16), 149(28) and 137(12); ν_{max} (KBr Disc)/ cm^{-1} 3329 and 1670.

k) Benzyl 3,4,5-trimethylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.220 g, 57%) was obtained from the reaction between N-methyl indole and the 5-acetoxymethyl-4-acetylpyrrole in toluene at

55°C, catalysed by toluene-4-sulphonic acid, it had m.p. 228-229°C (Found: C, 77.17; H, 5.73; N, 7.09. $C_{25}H_{22}N_2O_2 \cdot 0.33 H_2O$ requires C, 77.31; H, 5.88; N, 7.21%); $\delta_H([^2H_6]-DMSO)$ 11.28 (1H, s, 1-NH), 8.03 (1H, d, J7.5, 9-H), 7.88 (1H, s, 10-H), 7.56-7.34 (7H, m, ArH, 6-H, 7-H), 7.15-7.07 (1H, m, 8-H), 5.40 (2H, s, CH_2Ph), 4.02 (3H, s, 5- CH_3), 3.14 (3H, s, 4- CH_3) and 2.91 (3H, s, 3- CH_3); m/z (%) 382(M^+ , 72), 291(4), 274(100) and 91(34); $\nu_{max}(KBr Disc)/cm^{-1}$ 3337 and 1674.

1) Ethyl 1,3,4-trimethylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.060 g, 7%) was obtained from the reaction (2.5 mmol scale) between indole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 188-189°C (Found: C, 74.86; H, 6.32; N, 8.65), $C_{20}H_{20}N_2O_2$ requires C, 75.98; H, 6.29; N, 8.74%); $\delta_H([^2H_6]-DMSO)$ 10.66 (1H, s, 5-NH), 8.14 (1H, d, J7.7, 9-H), 8.03 (1H, s, 10-H), 7.45-7.31 (2H, m, 6-H, 7-H), 7.06-7.15 (1H, m, 8-H), 4.38 (2H, q, CH_2CH_3), 3.98 (3H, s, 1- CH_3), 2.91 (3H, s, 4- CH_3), 2.83 (3H, s, 3- CH_3) and 1.38 (3H, t, CH_2CH_3); m/z (%) 320(M^+ , 100), 306(10), 292(30), 247(8) and 231(10); $\nu_{max}(KBr Disc)/cm^{-1}$ 3385 and 1657.

m) Benzyl 1,3,4-trimethylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.240 g, 28%) was obtained from the reaction (2.7 mmol scale) between indole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 186-187°C (Found: C, 78.63; H, 5.83; N, 7.32, $C_{25}H_{22}N_2O_2$ requires C, 78.51; H, 5.80; N, 7.32%); $\delta_H([^2H_6]-DMSO)$ 10.66 (1H, s, 5-NH), 8.14 (1H, d, J7.4, 9-H), 8.02 (1H, s, 10-H), 7.56-7.31 (7H, m, ArH, 6-H, 7-H), 7.06-7.15 (1H, m, 8-H), 5.41 (2H, s, CH_2Ph), 3.98 (3H, s, 1- CH_3), 2.90 (3H, s, 4- CH_3) and 2.83 (3H, s, 3- CH_3); m/z (%) 382(M^+ , 100), 338(10), 291(44), 247(18) and 231(10); $\nu_{max}(KBr Disc)/cm^{-1}$ 3443 and 1697.

n) Ethyl 1,3,4,5-tetramethylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.220 g, 30%) was obtained from the reaction (2.2 mmol scale) between N-methylindole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 165.5-167°C (decomp.) (Found: C, 75.50; H, 6.65; N, 8.30, $C_{21}H_{22}N_2O_2$ requires C, 75.47; H, 6.63; N, 8.38%); $\delta_H([^2H_6]-DMSO)$ 8.15 (1 H, d, J7.5, 9-H), 8.07 (1H, s, 10-H), 7.50-7.38 (2H, m, 6-H, 7-H), 7.09-7.19 (1 H, m, 8-H), 4.38 (2 H, q, CH_2CH_3), 4.03 (3H, s, 5- CH_3), 3.96 (3H, s, 1- CH_3), 3.14 (3H, s, 4- CH_3), 2.84 (3H, s, 3- CH_3) and 1.39 (3H, t, CH_2CH_3); m/z (%) 334(100, M^+), 306(18) and 245(6); $\nu_{max}(KBr Disc)/cm^{-1}$ 1690 and 1528.

o) Benzyl 1,3,4,5-tetramethylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.070 g, 13%) was obtained from the reaction (1.4 mmol scale) between N-methylindole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 196-198°C (Found: C, 78.45; H, 6.16; N, 6.94, $C_{26}H_{24}N_2O_2$ requires C, 78.76; H, 6.10; N, 7.07%); $\delta_H([^2H_6]-DMSO)$ 8.15 (1 H d, J7.8, 9-H), 8.07 (1 H, s, 10-H), 7.59-7.29 (7H, m, ArH, 6-H, 7-H), 7.10-7.20 (1 H, m, 8-H), 5.42 (2H, s, CH_2Ph), 4.03 (3H, s, 5- CH_3), 3.97 (3H, s, 1- CH_3), 3.13 (3H, s, 4- CH_3) and 2.83(3H, s, 3- CH_3); m/z (%) 396(100, M^+), 305(38), 245(16) and 235(10); $\nu_{max} KBr Disc)/cm^{-1}$ 1696 and 1529.

p) Benzyl 3,4-dimethyl-5-(4-toluenesulphonyl)pyrrolo[3,2-b]carbazole-2-carboxylate

(0.012 g, 4%) was obtained from the reaction (0.6 mmol scale) between N-(4-toluenesulphonyl)indole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 270°C (Found: C, 70.83; H, 5.01; N, 5.23, $C_{31}H_{26}N_2O_4S$ requires C, 71.24; H, 5.01; N, 5.36%); $\delta_H([^2H_6]-DMSO)$ 11.58 (1H, s, N-H), 8.28-8.08 (3H, m, 6-H, 9-H, 10-H), 7.66-7.21 (11H, m, ArH, TsH, 7-H, 8-H), 5.40 (2H, s, CH_2Ph), 3.04 (3H, s, 4- CH_3), 2.88 (3H, s, 3- CH_3) and 2.20 (3H, s, Ts- CH_3); m/z (%) 523(30, $M+1$), 446(20), 367(30), 348(56), 33(100), 295(30) and 274(90); $\nu_{max}(KBr Disc)/cm^{-1}$ 3558 and 1666.

q) Ethyl 7-acetoxy-3,4-dimethyl-6-methoxypyrrolo[3,2-b]carbazole-2-carboxylate

(7%) obtained from the reaction between 6-acetoxy-7-methoxy-indole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 241-244°C. δ_H (CDCl₃) 8.59 (1H, s, br, NH), 7.78 (1H, s, br, NH), 7.76 (1H, s, 10-H), 7.74 (1H, d, J8, 9-H), 6.88 (1H, d, J8, 8-H), 4.44 (2H, q, CH₂CH₃), 4.04 (3H, s, 6-OCH₃), 2.96 and 2.92 (2 x 3H, 2 x s, 4-CH₃ and 3-CH₃), 2.42 (3H, s, 7-CH₃COO) and 1.46 (3H, t, CH₂CH₃); m/z (%) 394 (100, M⁺), 352 (47), 348 (33), 306 (87), 263 (21) and 87 (73); ν_{max} (Nujol)/cm⁻¹ 3413, 3341, 1739 and 1675; ν_{max}^+ (MeOH)/nm 405, 386, 339, 325, 305, 269, 240 and 226. (Found: M⁺, 394, 1529. C₂₂H₂₂N₂O₅ requires 394.1529).

r) Ethyl 9-methoxy-3,4,5-trimethylpyrrolo[3,2-b]carbazole-2-carboxylate

obtained from the reaction between 4-methoxy-1-methylindole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 263-266°C (Found: C, 71.84; H, 6.34; N, 7.91. C₂₁H₂₂N₂O₃ requires C, 71.98; H, 6.33; N, 7.99%; δ_H (CDCl₃) 8.60 (1H, s, br, NH), 8.15 (1H, s, 10-H), 7.40 (1H, t, J8, 7-H), 6.95 (1H, d, J8, 6-H), 6.66 (1H, d, J8, 8-H), 4.43 (2H, q, OCH₂CH₃), 4.10 and 4.04 (2 x 3H, 2 x s, N-CH₃ and OCH₃), 3.19 (3H, s, 4-CH₃), 2.98 (3H, s, 3-CH₃) and 1.46 (3H, t, OCH₂CH₃); m/z (%) 350 (74, M⁺), 304 (100), 276 (17), 223 (10) and 152 (19).

s) Benzyl 8-chloro-3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.069 g; 17%) was obtained from the reaction between 5-chloroindole and the 5-acetoxymethyl-4-acetylpyrrole, it had m.p. 215-220°C. (decomp.). (Found: C, 71.42; H, 4.96; N, 7.11,

$C_{24}H_{19}ClN_2O_2$ requires C, 71.55; H, 4.75; N, 6.95%; δ_H ($[^2H]_6$ -DMSO) 11.39 (1H, s, 1-NH), 10.84 (1H, s, 5-NH), 8.17 (1H, s, 9H), 7.93 (1H, s, 10-H), 7.54 (1H, d, J7, 7-H), 7.48-7.34 (6H, m, ArH and 6-H), 5.42 (2H, s, CH_2Ph) and 2.88 (6H, s, 3- CH_3 and 4- CH_3); m/z (%) 402 (30, M^+), 358(5), 294 (65), 267 (25) and 91 (100). The crystallisation liquors were submitted to flash chromatography on silica. Elution with ethyl acetate/light petroleum yielded further title compound which was crystallised from ethyl acetate (0.030g; 7%) and 3-(3'-acetyl-5'-benzyloxy-carbonyl-4'-methylpyrrol-2'-ylmethyl)-5-chloroindole as cream coloured crystals (0.152g; 36%) m.p. 141-143°C (Found: C, 68.20; H, 5.18; N, 6.60; $C_{24}H_{21}ClN_2O_3$ requires C, 68.49; H, 5.03; N, 6.65); δ_H ($CDCl_3$) 8.72 (1H, s, 1'-NH), 8.26 (1H, s, 1-NH), 7.38 (1H, d, J2, 4-H), 7.35 (6H, m, ArH and 6-H), 7.18 (1H, dd, J8 and 2, 2-H), 7.09 (1H, d, J2, 2-H), 5.23 (2H, s, CH_2Ph), 4.39 (2H, s, 3- CH_2), 2.64 (3H, s, 4'- CH_3) and 2.52 (3H, s, CH_3CO); m/z (%) 420 (20, M^+), 405 (10), 311 (20), 151 (15) and 91 (100).

t) Ethyl 3,4-dimethyl-8-hydroxypyrrolo[3,2-b]carbazole-2-carboxylate

Obtained from the reaction between 5-hydroxyindole and the 5-acetoxymethyl-4-acetylpyrrole and crystallised from methanol, it had m.p. 250°C (decomp.) δ_H ($[^2H]_6$ -DMSO) 11.11 (1H, s, 1-NH), 10.21 (1H, s, 5-NH), 8.83 (1H, s, OH), 7.73 (1H, s, 10-H), 7.37 (1H, d, J2.5, 9-H), 7.21 (1H, d, J8, 6-H), 6.87 (1H, dd, J8 and 2.5, 9-H), 7.21 (2H, q, OCH_2CH_3), 2.87 (3H, s, 4- CH_3), 2.84 (3H, s, 3- CH_3) and 1.38 (3H, t, OCH_2CH_3); m/z (%) 322 (69, M^+), 276 (100), 248 (24), 220(3) and 138 (15); (Found: M^+ , 322. 1322 $C_{19}H_{18}N_2O_3$ requires M, 322. 1317). Also isolated from the reaction was 3-(3'-acetyl-5'-ethoxycarbonyl-4'-methylpyrrol-2'-ylmethyl)-5-hydroxyindole, it had m.p. 99-102°C (Found: C, 66.89; H, 6.17; N, 8.03. $C_{19}H_{20}N_2O_4$ requires C, 67.04; H, 5.92; N, 8.23%); δ_H ($CDCl_3$) 8.84 (1H, s, 1'-NH), 8.14 (1H, s, 1-NH), 7.20 (1H, d, J8, 7-H), 7.10 (1H, d, J 2.5, 2-H), 6.81 (1H, d, J1.5,

4-H), 6.79 (1H, dd, J1.5 and 8, 6-H), 5.60 (1H, s, br, 5-OH), 4.31 (2H, s, CH₂), 4.21 (2H, q, OCH₂CH₃), 2.58 (3H, s, 4'-CH₃) 2.48 (3H, s, 3'-COCH₃) and 1.27 (3H, t, OCH₂CH₃); m/z (%) 340 (100, M⁺), 325 (44), 293 (21), 279 (35), 266 (35), 251 (31), 223 (25), 196 (5), 147 (20) and 133 (36).

u) Benzyl 3,4-dimethyl-7-fluoropyrrolo[3,2-b]carbazole-2-carboxylate and Benzyl 3,4-dimethyl-8-fluoro-pyrrolo[2,3-b]carbazole-2-carboxylate

obtained as a mixture of isomers from the reaction between 6-fluoroindole and the 5-acetoxymethyl-4-acetylpyrrole. Chromatographic separation yielded the [3,2-b]isomer (0.139g, 36%) m.p. 205°C (decomp.) δ_H ([²H₆]-DMSO) 11.32 (1H, s, 1-NH), 10.85 (1H, s, 5-NH), 8.08 (1H, dd, J9 and 6, 9-H), 7.86 (1H, s, 10-H), 7.57-7.35 (5H, m, ArH), 7.12 (1H, dd, J10 and 2, 6-H), 6.90 (1H, dt, J9 and 2, 8-H), 5.43 (2H, s, CH₂Ph), 2.91 (3H, s, 3-CH₃) and 2.90 (3H, s, 4-CH₃); m/z (%) 386 (55, M⁺), 342 (5), 295 (4), 278 (100), 249 (45), 236 (20), 222 (25) and 91 (95); (Found: MH⁺, 387.1509. C₂₄H₂₀FN₂O₂ requires 387.1509); and the [2,3-b]isomer m.p. 190-193°C δ_H (CDCl₃) 8.54 (1H, s, br, 1-NH), 8.10 (1H, dd, J9 and 6, 5-H), 7.87 (1H, s, br, 9-NH), 7.51-7.34 (5H, m, ArH), 7.34 (1H, s, 10-H), 7.22 (1H, dd, concealed by 10-H, 8-H), 6.93 (1H, dt, J2 and 9, 6-H), 5.41 (2H, s, CH₂Ph), 3.20 (3H, s, 4-CH₃) and 3.00 (3H, s, 3-CH₃); m/z (%) 386 (100, M⁺), 295 (12), 278 (96), 250 (27), 236 (7), 222 (8) and 91 (59); (Found: M⁺, 386.1433. C₂₄H₁₉FN₂O₂ requires 386.1431).

v) Ethyl 3,4-dimethyl-7-fluoropyrrolo[3,2-b]carbazole-2-carboxylate and Ethyl 3,4-dimethyl-8-fluoropyrrolo[2,3-b]carbazole-2-carboxylate

obtained as a mixture of isomers from the reaction between 6-fluoroindole and the 5-acetoxymethyl-4-acetylpyrrole. Chromatographic separation yielded the [3,2-b]isomer which was

crystallised from dichloromethane, m.p. 231-234°C (Found: C, 70.45; H, 5.53; N, 8.66. $C_{19}H_{17}FN_2O_2$ requires C, 70.36, H, 5.28; N, 8.64%); $\delta_H([^2H_6]-DMSO)$ 11.27 (1H, s, br, 1-NH), 10.82 (1H, s, br, 5-NH), 8.90 (1H, dd, J9 and 6, 9-H), 7.85 (1H, s, 10-H), 7.12 (1H, dd, J10 and 2, 6-H) 6.89 (1H, dt, J2 and 9, 8-H), 4.37 (2H, q, OCH_2CH_3) 2.89 (6H, s, 4- CH_3), 1.39 (3H, t, OCH_2CH_3); m/z (%) 324 (60, M^+), 278 (100), 250 (34), 222 (10) and 139 (7); (Found: M^+ , 324.1267. $C_{19}H_{17}FN_2O_2$ requires 324.1274); and the [2,3-b]isomer m.p. 262-265°C; $\delta_H([^2H_6]-DMSO)$ 11.14 (1H, s, br, 1-NH), 11.06 (1H, s, br, 9-NH), 8.12 (1H, dd J 6 and 9, 5-H), 7.19 (1H, s, 10-H), 7.15 (1H, dd J10 and 2, 8-H), 6.92 (1H, dt, J2 and 9, 6-H), 4.36 (2H, q, OCH_2CH_3), 3.13 (3H, s, 4- CH_3), 2.93 (3H, s, 3- CH_3) and 1.39 (3H, t, OCH_2CH_3); m/z (%) 324 (72, M^+), 278 (100), 250 (39), 222 (9), 139(6) and 125(7); (Found: M^+ , 324.1280. $C_{19}H_{17}FN_2O_2$ requires 324.1274).

w) Ethyl 3,4-dimethyl-9-hydroxypyrrolo[3,2-b]carbazole-2-carboxylate and Ethyl 3,4-dimethyl-5-hydroxypyrrolo[3,2-b]carbazole-2-carboxylate

obtained as a mixture of isomers from the reaction between 4-hydroxyindole and the 5-acetoxymethyl-4-acetylpyrrole. Chromatographic separation yielded the [3,2-b]isomer which was crystallised from ethyl acetate/light petroleum, m.p. 260-262°C (decomp.) $\delta_d([^2H_6]-DMSO)$ 11.13 (1H, s, 1-NH), 10.56 (1H, s, 5-NH), 10.00 (1H, s, OH), 8.02 (1H, s, 10-H), 7.12 (1H, t, J7.5, 7-H), 6.83 (1H, d, J7.5, 6-H), 6.48 (1H, d, J7.5, 8-H), 4.39 (2H, q, OCH_2CH_3), 2.87 (3H, s, 4- CH_3), 2.85 (3H, s, 3- CH_3) and 1.38 (3H, t, OCH_2CH_3); m/z (%) 322 (61, M^+), 276 (100), 248 (20), 219 (5) and 138 (11); (Found: M^+ , 322.1305. $C_{19}H_{18}N_2O_3$ requires 322.1317); and the [2,3-b]isomer which was crystallised from ethyl acetate, m.p. 251-254°C (decomp.) $\delta_H([^2H_6]-DMSO)$ 10.95 (1H, s, 1-NH), 10.85 (1H, s, 9-H), 9.89 (1H, s, OH), 7.08 (1H, t, J7.5, 7-H), 7.07 (1H, s, 10-H), 6.77 (1H, d, J7.5, 8-H), 6.52 (1H, d, J7.5, 7-H), 4.32 (2H, q, OCH_2CH_3), 3.44 (3H, s,

4-CH₃), 2.92 (3H, s, 3-CH₃) and 1.37 (3H, t, OCH₂CH₃); m/z (%) 322 (65, M⁺), 276 (100), 248 (88), 219 (15), 205 (10), 191 (10), 178 (5), 165 (5), 138 (10) and 115 (10); (Found: M⁺, 322.1317. C₁₉H₁₈N₂O₃ requires 322.1317).

- x) Ethyl 6,9-dimethoxy-3,4-dimethylpyrrole[3,2-b]carbazole-2-carboxylate and Ethyl 5,8-dimethoxy-3,4-dimethylpyrrole[2,3-b]carbazole-2-carboxylate

obtained as a mixture of isomers from the reaction between 4,7-dimethoxyindole and the 5-acetoxymethyl-4-acetylpyrrole. Chromatographic separation yielded the [3,2-b]isomer (13.7%) m.p. 256-258°C. (Found: C, 68.98; H, 6.23; N, 7.89. C₂₁H₂₂N₂O₄ requires C, 68.84; H, 6.05; N, 7.65%). δ_H (CDCl₃) 8.58 (1H, s, br, NH), 8.08 (1H, s, 10-H), 7.84 (1H, s, br, NH), 6.82 (1H, d, J₈, 7-H), 6.50 (1H, d, J₈, 8-H), 4.43 (2H, q, OCH₂CH₃), 4.05 (3H, s, 9-OCH₃), 3.98 (3H, s, 6-OCH₃), 2.96 (3H, s, 4-CH₃), 2.92 (3H, s, 3-CH₃) and 1.44 (3H, t, OCH₂CH₃); m/z (%) 366 (73, M⁺), 326 (100), 305 (11), 290 (11), 277 (23), 262 (15), 183 (10), 160 (17), 152 (19) and 131 (7); ν_{max} (Nujol)/cm⁻¹ 3474, 3323 and 1674; λ_{max} (MeOH)/nm 415, 387, 344, 330(sh), 305(sh), 266, 246 and 220; and the [2,3-b]isomer (9.3%) m.p. 193-195°C. (Found: C, 69.03; H, 6.29; N, 7.42. C₂₁H₂₂N₂O₄ requires C, 68.84; H, 6.05; N, 7.65%). δ_H (CDCl₃) 8.44 (1H, s, br, NH), 8.10 (1H, s, br, NH), 7.06 (1H, s, 10-H), 6.82 (1H, d, J₈, 7-H), 6.56 (1H, d, J₈, 6-H), 4.40 (2H, q, OCH₂CH₃), 3.98 (3H, s, OCH₃), 3.97 (3H, s, OCH₃), 3.42 (3H, s, 4-CH₃), 3.00 (3H, s, 3-CH₃) and 1.43 (3H, t, OCH₂CH₃); m/z (%) 366 (100, M⁺), 320 (82), 292 (20), 277 (24), 262 (10), 183 (14), 160 (28), 131 (3); ν_{max} (Nujol)/cm⁻¹ 3457, 3345 and 1660; λ_{max} (MeOH)/nm 381, 365, 293, 247 and 219.

- y) Ethyl 7-methoxy-3,4-dimethylpyrrole[3,2-b]carbazole-2-carboxylate and Ethyl 7-methoxy-3,4-dimethylpyrrole[2,3-b]carbazole-2-carboxylate

obtained as a mixture of isomers from the reaction between 6-methoxyindole and the 5-acetoxymethyl-4-acetylpyrrole. Flash chromatography on silica, eluting with ethyl acetate/cyclohexane (1:1) yielded the [3,2-b]isomer which was crystallised from ethylacetate/cyclohexane, m.p. 239-241°C (decomp.) $\delta_{\text{H}}([{}^2\text{H}_6]\text{-DMSO})$ 11.09 (1H, s, 1-NH), 10.49 (1H, s, 5-NH), 7.91 (1H, d, J 8.7, 9-H), 7.73 (1H, s, 10-H), 6.88 (1H, d, J 2.3, 6-H), 6.68 (1H, dd, J 8.7 and 2.3, 8-H), 4.35 (2H, q, OCH_2CH_3), 3.84 (3H, s, 7-OCH₃), 2.87 (3H, s, 3-CH₃), 2.86 (3H, s, 4-CH₃) and 1.37 (3H, t, OCH_2CH_3); m/z (%) 336 (84, M^+), 290 (100), 262 (32), 247 (16) and 219 (16); ν_{max} (KBr Disc)/cm⁻¹ 3342, 1674 and 1628; and the [2,3-b]isomer which was crystallised from ethyl acetate/cyclohexane, m.p. 260°C (decomp.) $\delta_{\text{H}}([{}^2\text{H}_6]\text{-DMSO})$ 10.98 (1H, s, 1-NH), 10.74 (1H, s, 9-NH), 8.00 (1H, d, J 8.7, 5-H), 7.13 (1H, s, 10-H), 6.87 (1H, d, J 2.7, 8-H), 6.70 (1H, dd, J 8.7 and 2.7, 6-H), 4.34 (2H, q, OCH_2CH_3), 3.83 (3H, s, 7-OCH₃), 3.10 (3H, s, 4-CH₃), 2.91 (3H, s, 3-CH₃) and 1.37 (3H, t, OCH_2CH_3); m/z (%) 336 (56, M^+), 290 (70), 262 (26), 145 (16), 129 (14); ν_{max} (KBr Disc)/cm⁻¹ 3379, 3339 and 1663.

z) Ethyl 3-ethyl-4-methylpyrrolo[3,2-b]carbazole-2-carboxylate

(0.956g, 27%) was obtained from the reaction (11 mmol scale) between indole and the ethyl 5-acetoxymethyl-4-acetyl-3-ethylpyrrole-2-carboxylate, after recrystallisation from toluene, it had m.p. 248-249°C (decomp.) (Found: C, 74.93; H, 6.35; N, 8.60. $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_2$ requires: C, 74.98; H, 6.29; N, 8.74%); $\delta_{\text{H}}([{}^2\text{H}_6]\text{-DMSO})$ 11.27 (1H, s, 1-NH), 10.63 (1H, s, 5-NH), 8.09 (1H, d, J 8, 9-H), 7.93 (1H, s, 10-H), 7.31-7.47 (2H, m, 6-H, 7-H), 7.09 (1H, ddd, J 8, 5.5, 2, 8-H), 4.40 (2H, q, J 7, CO_2CH_2), 3.37 (2H, q, J 7, 3-CH₂), 2.91 (3H, s, 4-CH₃), 1.41 (3H, t, J 7, $\text{CO}_2\text{CH}_2\text{CH}_3$), 1.30 (3H, t, J 7.5, 3-CH₂CH₃); m/z (%) 320 (100, M^+), 274 (96); ν_{max} (KBr disc)/cm⁻¹ 3344, 3327, 1680, 1664, 1238.

Example 5Pyrrolo[3,2-b]carbazole-2-carboxylic Acids General procedure.

To a solution of the benzyl pyrrolo[3,2-b]carbazole-2-carboxylate in dry tetrahydrofuran (THF) (10 cm³) was added 10% Pd-on-C (50 mg). The reaction mixture was hydrogenated at one atmos. pressure and room temperature. After uptake of H₂ had ceased, the catalyst was removed by filtration through Celite and washed well with THF, and the combined filtrates were evaporated under reduced pressure. Crystallisation of the resulting solid from acetone, methyl ethyl ketone or aqueous methanol gave the pyrrolo[3,2-b]carbazole-2-carboxylic acids as yellow crystals.

a) 3,4-Dimethylpyrrolo[3,2-b]carbazole-2-carboxylic acid

(0.234 g, 84.3%) m.p. 237°C (decomp.); $\delta_{\text{H}}([^2\text{H}_6]\text{-DMSO})$ 12.74 (1 H, br, s, CO₂H), 11.13 (1 H, s, 1-NH), 10.60 (1 H, s, 5-NH), 8.05 (1 H, d, J7.5, 9-H), 7.87 (1 H, s, 10-H), 7.42 (1 H, d, J7.5, 6-H), 7.36 (1 H, t, J7.5, 7-H), 7.08 (1 H, t, J7.5, 8-H), 2.92 and 2.91 (2 x 3H, 2 x s, 3-CH₃ and 4-CH₃); m/z (%) 278(30, M⁺), 260(39), 234(100), 218(19), 204(8), 167(8), 149(16), 130(10) and 117(25) (Found: M⁺, 278.1060. C₁₇H₁₄N₂O₂ requires M, 278.1055).

b) 8-Fluoro-3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylic acid

(0.0845 g, 85.6%) m.p. 236-239 °C, $\delta_{\text{H}}([^2\text{H}_6]\text{-DMSO})$ 12.80 (1 H, br, s, CO₂H), 11.19 (1 H, s, 1-NH), 10.60 (1 H, s, 5-NH), 7.91 (1 H, dd, J9 and 2.5, 9-H), 7.86 (1 H, s, 10-H), 7.37 (1 H, dd, J9 and 4,6-H), 7.20 (1 H, dt, J9 and 2.5, 7-H) and 2.89 (6 H, s, 2xCH₃); m/z (%) 296(51, M⁺), 278(71), 252(100), 250(37), 236(19), 222(13), 139(22), 125(36) and 111(28) (Found: M⁺, 296.0960. C₁₇H₁₃FN₂O₂ requires M, 296.0961)

c) 3,4,6-Trimethylpyrrolo[3,2-b]carbazole-2-carboxylic acid

(0.065 g, 85%) m.p. 230°C (decomp.) (Found: C, 74.2; H, 5.55; N, 9.4 C₁₈H₁₆N₂O₂ requires C, 74.0; H, 5.52; N, 9.58%);
 $\delta_{\text{H}}([^2\text{H}_6]\text{-DMSO})$ 12.80 (1 H, br, s, CO₂H), 11.01 (1 H, s, 1-NH), 10.08 (1 H, s, 5-NH), 7.90 (1 H, d, J 7.5, 9-H), 7.82 (1 H, s, 10-H), 7.16 (1 H, d, J 7.5, 7-H), 7.01 (1 H, t, J 7.5, 8-H), 2.97 (3 H, s, 4-CH₃), 2.92 (3H, s, 3-CH₃) and 2.58 (3 H, s, 6-CH₃);
 m/z(%) 292(72, M⁺), 274(100), 246(50), 230(11), 137(25), 122(24) and 109(30).

d) 3-(2-Methoxycarbonyl-ethyl)-4-methylpyrrolo[3,2-b]carbazole-2-carboxylic acid

(0.0673 g, 84.6%) m.p. 255°C (decomp.) (Found: C, 68.4; H, 5.3; N, 7.75. C₂₀H₁₈N₂O₄ requires C, 68.6; H, 5.18; N, 8.00%);
 $\delta_{\text{H}}([^2\text{H}_6]\text{-DMSO})$ 12.88 (1 H, br, s, CO₂H), 11.34 (1 H, s, 1-NH), 10.65 (1 H, s, 5-NH), 8.06 (1 H, d, J 7.5, 9-H), 7.88 (1 H, s, 10-H), 7.42 (1 H, d, J 7.5, 6-H), 7.36 (1 H, t, J 7.5, 7-H) 7.07 (1 H, t, J 7.5, 8-H), 3.66 (3 H, s, OCH₃), 3.63 (2 H, partially obscured t, CH₂CH₂CO), 2.89 (3 H, s, 4-CH₃), 2.66 (2 H, t, CH₂CO); m/z(%) 350(100, M⁺), 332(17), 306(30), 290(63), 272(22), 259(32) and 233(47).

e) 1,3,4-Trimethylpyrrolo[3,2-b]carbazole-2-carboxylic acid

(0.060 g, 44%) m.p. 215-216°C (decomp.) (Found: C, 73.69; H, 5.51; N, 9.41; C₁₈H₁₆N₂O₂ requires c, 73.95; H, 5.52; N, 9.58);
 $\delta_{\text{H}}([^2\text{H}_6]\text{-DMSO})$ 12.94 (1H, br, s, COOH), 10.63 (1H, s, 5-NH), 8.13 (1H, d, J 7.9, 9-H), 8.00 (1H, s, 10-H), 7.45-7.30 (2H, m, 6-H, 7-H), 7.14-7.04 (1H, m, 8-H), 3.99 (3H, s, 1-CH₃), 2.91 (3H, s, 4-CH₃) and 2.85 (3H, s, 3-CH₃); m/z (%) 292(95, M⁺), 275(10), 247(40), 232(30), 180(100) and 135(100); ν_{max} (KBr Disc)/cm⁻¹ 3375, 2930 and 1709.

f) 3,4,5-Trimethylpyrrolo[3,2-b]carbazole-2-carboxylic acid

(0.015 g, 18%) m.p. 239-240°C (decomp.) (Found: C, 74.11; H, 5.38; N, 9.39; $C_{18}H_{16}N_2O_2$ requires C, 73.95; H, 5.52; N, 9.58; $\delta_H([^2H_6]-DMSO)$ 11.15 (1H, s, 1-NH), 8.04 (1H, d, J 7.5, 9-H), 7.88 (1H, s, 10-H), 7.48-7.41 (2H, m, 6-H, 7-H), 7.17-7.06 (1H, m, 8-H), 4.03 (3H, s, 5-CH₃), 3.16 (3H, s, 4-CH₃) and 2.93 (3H, s, 3-CH₃); m/z (%) 292(90, M⁺), 274(75), 232(70), 197(35), 181(60), 149(30) and 130(100); ν_{max} (KBr Disc)/cm⁻¹ 3454, 2926 and 1670.

g) 1,3,4,5-Tetramethylpyrrolo[3,2-b]carbazole-2-carboxylic acid

(0.030 g, 32%) m.p. 215-217°C (decomp.) (Found: C, 74.44; H, 6.00; N, 9.14; $C_{19}H_{18}N_2O_2$ requires C, 74.49; H, 5.92; N, 9.14); $\delta_H([^2H_6]-DMSO)$ 12.98 (1H, br, s, COOH), 8.14 (1H, d, J 7.6, 9-H), 8.04 (1H, s, 10-H), 7.48-7.38 (2H, m, 6-H, 7-H), 7.18-7.08 (1H, m, 8-H), 4.01 (3H, s, 5-CH₃), 3.97 (3H, s, 1-CH₃), 3.12 (3H, s, 4-CH₃) and 2.84 (3H, s, 3-CH₃); m/z (%) 306(100, M⁺), 279(25), 232(38), 197(34), 181(80) and 149(25); ν_{max} (KBr Disc)/cm⁻¹ 1935 and 1659.

h) 3,4-Dimethylpyrrolo[3,2-b]carbazole-2-carboxylic acid

The ethyl ester (500mg, 1.6mmol) in water (15 cm³) and methanol (35 cm³) was heated to reflux and sufficient methanol to achieve dissolution was added. Caesium carbonate (5.32g; 16mmol) was added and the mixture was heated to reflux under nitrogen for 18h. After cooling, solvent was removed in vacuo to leave approximately 20 cm³ of solution which was brought to pH3 by the addition of 0.1M hydrochloric acid whereupon the title compound precipitated out. Filtration, washing with water and drying under vacuum yielded analytically pure product (437mg; 96%) which was spectroscopically identical to that obtained in Example 5a.

Example 6Pyrrolo[3,2-b]carbazole-2-carboxylic Acid Esters - General procedure

The pyrrolo[3,2-b]carbazole-2-carboxylic acid (1.0 mmol) and N,N'-carbonyl diimidazole (1.1 mmol) were dissolved in freshly distilled tetrahydrofuran under a nitrogen atmosphere. The resulting suspension was stirred at room temperature for at least one hour, and complete conversion of the acid to the imidazolide intermediate was verified by TLC. The alcohol or phenol (1.5-2.0 mmol, i.e. an excess) was added in one portion, and the resulting mixture was heated to reflux until TLC showed complete consumption of the imidazolide intermediate. The product was obtained by column chromatography on silica, followed by recrystallisation.

a) Phenyl 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

was obtained from the reaction of the imidazolide intermediate with phenol. Chromatography (eluting with 10% acetone/90% petrol) followed by recrystallisation from acetone-petrol gave orange crystals (0.230 g, 65%) m.p. $>230^{\circ}\text{C}$ (decomp.) (Found: C, 78.17; H, 5.09; N, 7.77. $\text{C}_{23}\text{H}_{18}\text{N}_2\text{O}_2$ requires C, 77.95; H, 5.12; N, 7.90%); δ ($^2\text{H}_6$)-DMSO) 11.55 (1H, s, 1-NH), 10.64 (1H, s, 5-NH), 8.10 (1H, d, J 7.5, 9-H), 7.94 (1H, s, 10-H), 7.30-7.58 (7H, m, PhH, 6-H, 7-H), 7.09 (1H, ddd, J 7.5, 5.5, 2, 8-H) and 2.97 and 2.95 (2 x 3H, 2 x s, 3-CH₃ and 4-CH₃); m/z(%) 355(40, M^+); ν_{max} (KBr Disc)/ cm^{-1} 3396, 1701 and 1180.

b) [(2-Dimethylamino)ethyl] 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

was obtained from the reaction of the imidazolide intermediate with (2-dimethylamino)ethanol. Chromatography (eluting with 10% methanol/90% DCM) gave a yellow solid (0.350 g, 99%).

Recrystallisation of a portion from DCM gave yellow crystals with m.p. 174.0-175.7°C (decomp.) (Found: C, 70.46; H, 6.48; N, 11.76. $C_{21}H_{23}N_3O_2 \cdot 0.15CH_2Cl_2$ requires C, 70.29; H, 6.45; N, 11.55%); δ_H ($[^2H_6]$ -DMSO) 11.18 (1H, s, 1-NH), 10.60 (1H, s, 5-NH), 8.07 (1H, d, J 8, 9-H), 7.89 (1H, s, 10-H), 7.30-7.43 (2H, m, 6-H, 7-H), 7.09 (1H, ddd, J 8, 6, 2.5, 8-H), 4.41 (2H, t, J 6, OCH_2), 2.91 (6H, s, 3- CH_3 and 4- CH_3), 2.69 (2H, t, J 6.0, NCH_2) and 2.27 (6H, s, $N(CH_3)_2$); m/z (%) 350(46, $(M+1)^+$), 261(68) and 133(100); ν_{max} (KBr Disc)/ cm^{-1} 3377, 1661 and 1238.

c) [(3-Dimethylamino)phenyl] 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

was obtained from the 0.95 mmol scale reaction of the imidazolidine intermediate with (3-dimethylamino)phenol. Chromatography (eluting with 10% ethyl acetate/90% toluene) followed by recrystallisation from ethyl acetate gave yellow crystals (0.272 g, 72%) m.p. 240-242°C (decomp.) (Found: C, 75.37; H, 5.71; N, 10.36. $C_{25}H_{23}N_3O_2$ requires C, 75.55; H, 5.83; N, 10.57%; δ_H ($[^2H_6]$ -DMSO) 11.49 (1H, s, 1-NH), 10.64 (1H, s, 5-NH), 8.08 (1H, d, J 8, 9-H), 7.91 (1H, s, 10-H), 7.34-7.48 (2H, m, 6-H, 7-H), 7.27 (1H, t, J 8, 5'-H), 7.10 (1H, ddd, J 8, 6, 2, 8-H), 6.56-6.70 (3H, m, 2'-H, 4'-H, 6'-H), 2.96 (3H, s) and 2.94 (9H, s) (3- CH_3 , 4- CH_3 , $N(CH_3)_2$); m/z (%) 398(38, $(M+1)^+$), 261(25), 232(21) and 217(100); ν_{max} (KBr Disc)/ cm^{-1} 3350, 1674, 1610 and 1232.

d) (3-Pyridyl) 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

was obtained from the reaction of the imidazolidine intermediate with 3-hydroxypyridine. Chromatography (eluting with 50% ethyl acetate/50% petrol) followed by recrystallisation from acetone gave yellow crystals (0.230 g, 65%) with m.p. >270°C (decomp.) (Found: C, 73.88; H, 4.76; N, 11.50. $C_{22}H_{17}N_3O_2 \cdot 0.2H_2O$ requires: C, 73.61; H, 4.89; N, 11.71%); δ_H ($[^2H_6]$ -DMSO) 11.59

(1H, s, 1-NH), 10.65 (1H, s, 5-NH), 8.63 (1H, d, J 2, 2'-H), 8.55 (1H, dd, J 4, 1, 6'-H), 8.10 (1H, d, J 8, 9-H), 7.90 (1H, s, 10-H), 7.86 (1H, ddd, J 8, 3, 1, 5'-H), 7.58 (1H, dd, J 8, 5, 4'-H), 7.32-7.45 (2H, m, 6-H, 7-H), 7.09 (1H, ddd, J 8, 6, 2, 8-H) and 2.97 and 2.94 (2 x 3H, 2 x s, 3-CH₃ and 4-CH₃); m/z (%) 356(15, (M+1)⁺). ν_{\max} (KBr Disc)/cm⁻¹ 3377, 1715 and 1173.

e) (4-Carbamoylphenyl) 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

was obtained from the reaction of the imidazolidine intermediate with 3-hydroxybenzamide. Recrystallisation from ethanol gave a yellow powder, and an impure residue. The latter material was further purified by column chromatography on silica (eluted with 5% methanol/95% DCM then 10% methanol/90% DCM) followed by recrystallisation from ethanol. (0.262 g, 66%) m.p. >250°C (decomp.) (Found: C, 71.72; H, 4.81; N, 10.26. C₂₄H₁₉N₃O₃·0.2H₂O requires C, 71.88; H, 4.88; N, 10.48%); δ_{H} ([²H₆]-DMSO 11.56 (1H, s, 1-NH), 10.63 (1H, s, 5-NH), 7.90-8.12 (5H, m, 9-H, 10-H, 3'-H, 5'-H, amide N-H), 7.33-7.49 (5H, m, 6-H, 7-H, 2'-H, 6'-H, amide N-H), 7.09 (1H, ddd, J 8.5, 6, 1.5, 8-H) and 2.95 and 2.93 (2 x 3H, 2 x s, 3-CH₃ and 4-CH₃); m/z (%) 398(10, (M+1)⁺), 279(100); ν_{\max} (KBr Disc)/cm⁻¹ 3423, 1717, 1695 and 1171.

f) (Pyridyl-4-methyl) 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

was obtained from the reaction of the imidazolidine intermediate with 4-pyridylcarbinol. Chromatography (eluting with ethyl acetate/petrol, gradient 60%, 80%, 100% ethyl acetate, then methanol/ethyl acetate, gradient 10%, 20%) followed by recrystallisation from tetrahydrofuran gave orange crystals (0.168 g, 46%) with m.p. >240°C (decomp.) (Found: C, 72.16; H, 5.12; N, 10.73. C₂₃H₁₉N₃O₂·0.7H₂O requires C, 72.31; H, 5.38; N, 11.00%); δ_{H} ([²H₆]-DMSO 11.31 (1H, s, 1-NH), 10.62 (1H, s, 5-NH),

8.62 (2H, dd, J 4.5, 0.5, 2'-H, 6'-H), 8.08 (1H, d, J 7.5, 9-H), 7.89 (1H, s, 10-H), 7.53 (2H, d, J 5.5, 3'-H, 5'-H), 7.32-7.43 (2H, m, 6-H, 7-H), 7.07 (1H, ddd, J 8, 5, 1, 8-H), 5.45 (2H, s, ArCH_2) and 2.94 and 2.92 (2 x 3H, 2 x 3- CH_3 and 4- CH_3); m/z (%) 369(27, $(\text{M}+1)^+$), 327(70) and 295(100); ν_{max} (KBr Disc)/ cm^{-1} 3400, 1709 and 1232.

g) (1,3-Dibenzoyloxypropyl-2) 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

was obtained from the 1.5 mmol scale reaction of the imidazolidine intermediate with (1,3-dibenzoyloxy-2-propanol). Chromatography (eluting with 20% ethyl acetate/80% toluene then 40% ethyl acetate/60% toluene) followed by recrystallisation from ethyl acetate-ether-petrol gave yellow crystals (0.776 g, 97%) m.p. 124.8-126°C (decomp.) (Found: C, 76.35; H, 6.07; N, 5.12. $\text{C}_{34}\text{H}_{32}\text{N}_2\text{O}_4$ requires C, 76.67; H, 6.06; N, 5.26%; δ_{H} ($[\text{H}_6]$ -DMSO) 11.18 (1H, s, 1-NH), 10.60 (1H, s, 5-NH), 8.06 (1H, d, J 7.5, 9-H), 7.88 (1H, s, 10-H), 7.22-7.42 (12H, m, 2 x PhH_5 , 6-H, 7-H), 7.07 (1H, ddd, J 8, 6.5, 1.5, 8-H), 5.44 (1H, quintet, J 5, 1'-H), 4.60 and 4.53 (2 x 2H, 2 x dd, J 12, 2 x PhCH_2O), 3.77 (4H, d, J 5.5, $\text{OCH}(\text{CH}_2)_2$) and 2.91 and 2.89 (2 x 3H, 2 x s, 3- CH_3 and 4- CH_3); m/z (%) 532(50, M^+), 260(65) and 91(100); ν_{max} (KBr Disc)/ cm^{-1} 3358, 1681 and 1234.

h) (4-Methylsulphinyphenyl) 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

was obtained from the reaction of the imidazolidine intermediate with 4-methylsulphinyphenol. Chromatography (eluting with ethyl acetate/petrol, gradient 90%, 95%, 98%, 100% ethyl acetate, then 10% methanol/ethyl acetate) followed by recrystallisation from tetrahydrofuran gave a yellow powder (0.261 g, 63%) m.p. >230°C (decomp.) (Found: C, 68.40; H, 4.81; N, 6.44. $\text{C}_{24}\text{H}_{20}\text{N}_2\text{O}_3\text{S} \cdot 0.3\text{H}_2\text{O}$ requires C, 68.32; H, 4.92; N,

6.64%; $\delta_{\text{H}}([{}^2\text{H}_6]\text{-DMSO})$ 11.59 (1H, s, 1-NH), 10.68 (1H, s, 5-NH), 8.10 (1H, d, J 8, 9-H), 7.93 (1H, s, 10-H), 7.82 (2H, d, J 9.5, 3'-H, 5'-H), 7.59 (2H, d, J 9.5, 2'-H, 6'-H), 7.33-7.45 (2H, m, 6-H, 7-H), 7.09 (1H, ddd, J 8, 6, 2.5, 8-H), 2.99 and 2.95 (2 x 3H, 2 x s, 3-CH₃ and 4-CH₃) and 2.82 (3H, s, CH₃SO); m/z (%) 417(2, M+1⁺), 261(100) and 233(75); ν_{max} (KBr Disc/cm⁻¹) 3427, 3288, 1717 and 1200.

i) Methyl 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

was obtained from the reaction of the imidazolidine intermediate with methanol. Chromatography (eluting with 30% ethyl acetate/petrol), followed by recrystallisation from ethyl acetate gave a yellow powder (0.188g, 64%) with m.p. 211-213°C (decomp.) (Found: C, 74.06, H, 5.49, N, 9.42, C₁₈H₁₆N₂O₂ requires: C, 73.95; H, 5.52; N, 9.58%); $\delta_{\text{H}}([{}^2\text{H}_6]\text{-DMSO})$ 11.25 (1H, s, 1-NH), 10.62 (1H, s, 5-NH), 8.08 (1H, d, J 8, 9-H), 7.89 (1H, s, 10-H), 7.33-7.58 (2H, m, 6-H, 7-H), 7.09 (1H, ddd, J 8, 6, 1, 8-H), 3.92 (3H, s, OCH₃), 2.92 and 2.91 (2 x 3H, 2 x s, 3-CH₃ and 4-CH₃); m/z (%) 292(68, M⁺), 260(100), 232(39); ν_{max} (KBr disc)/cm⁻¹ 3342, 1684 and 1236.

j) [(2-Methylsulphonyl)ethyl]3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

Was obtained from the reaction of the imidazolidine intermediate with (2-methylsulphonyl)ethanol. Chromatography (gradient elution with ethyl acetate/petrol, 30% - 100%) followed by recrystallisation from acetone gave fine yellow crystals (0.222 g, 58%) with m.p. 255-257°C (decomp.) (Found: C, 62.23; H, 5.25; N, 7.08. C₂₀H₂₀N₂O₄S requires C, 62.48; H, 5.24; N, 7.29%); $\delta_{\text{H}}([{}^2\text{H}_6]\text{-DMSO})$ 11.19 (1H, s, 1-NH), 10.60 (1H, s, 5-NH), 8.09 (1H, d, J 7.5, 9-H), 7.89 (1H, s, 10-H), 7.32-7.45 (2H, m, 6-H, 7-H), 7.09 (1H, ddd, J 7.5, 5.5, 3, 8-H), 4.69 (2H, t, J 5.5, OCH₂), 3.69 (2H, t, J 5.5, SO₂CH₂), 3.12 (3H, s, SO₂CH₃), 2.93 (6H, s,

3-CH₃ and 4-CH₃); m/z (%) 384 (17, M⁺), 260(13), 59(100); ν_{\max} (KBr disc)/cm⁻¹ 3387, 1661, 1234.

k) Tert-butyl 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate

The pyrrolo[3,2-b]carbazole-2-carboxylic acid (0.86 mmol) and triphenylphosphine (0.91 mmol, 1.05 eq.) were dissolved in freshly distilled tetrahydrofuran under a nitrogen atmosphere. Tertiary-butanol (2.12 mmol, 2.5 eq.) was added by syringe, and finally diethyl azodicarboxylate (0.95 mmol, 1.1 eq.) was added dropwise over 10 minutes. The resulting suspension was stirred at room temperature for two hours, by which time TLC showed complete consumption of the starting acid. The title compound was obtained from the crude reaction mixture in several stages: column chromatography on silica, eluting with 20% ether/80% petrol then 50% ether/50% petrol; column chromatography on silica (eluting with 25% ether/75% petrol then 40% ether/60% petrol); and finally, recrystallisation from DCM gave yellow powder (0.030 g, 10%) m.p. 187-189°C (decomp.) (Found: C, 73.24; H, 6.53; N, 7.93. C₂₁H₂₂N₂O₂·0.15CH₂Cl₂ requires C, 73.18; H, 6.47; N, 8.07%); δ_{H} ([²H₆]-DMSO) 10.95 (1H, s, 1-NH), 10.57 (1H, s, 5-NH), 8.05 (1H, d, J 8, 9-H), 7.88 (1H, s, 10-H), 7.29-7.43 (2H, m, 6-H, 7-H), 7.05 (1H, ddd, J 8, 6, 1, 8-H), 2.89 and 2.87 (2 x 3H, 2 x s, 3-CH₃ and 4-CH₃) and 1.59 (9H, s, C(CH₃)₃); m/z (%) 355(62, M+1⁺), 278(90), 233(38), 126(32), 91(78) and 57(100); ν_{\max} (KBr Disc)/cm⁻¹ 3337, 1664 and 1240.

Example 7

Pyrrolo[3,2-b]carbazole-2-carboxylic Acid Amides

a) 3,4-Dimethyl-2-(1-imidazolylcarbonyl)pyrrolo[3,2-b]carbazole

3,4-Dimethylpyrrolo[3,2-b]carbazole-2-carboxylic acid (0.280 g, 1.0 mmol) and N,N'-carbonyldiimidazole (0.164 g, 1.0 mmol) were dissolved in freshly distilled tetrahydrofuran (5 cm³) under a

nitrogen atmosphere. The resulting suspension was stirred at room temperature for two hours, and complete conversion of the acid to the imidazolid was verified by TLC. The THF was removed and the residue recrystallised from ethyl acetate to give the product as a yellow solid (0.125 g, 38%) m.p. 252°C (decomp.) (Found: C, 73.17; H, 4.87; N, 16.80, $C_{20}H_{16}N_4O$ requires: C, 73.15; H, 4.91; N, 17.06%); $\delta_H([^2H_6]-DMSO)$ 11.53 (1H, s, 1-NH), 10.20 (1H, s, 5-NH), 8.30 (1H, s, 2'-H), 8.12 (1H, d, J8, 9-H), 7.94 (1H, s, 10-H), 7.79 (1H, s, 5'-H), 7.33-7.47 (2H, m, 6-H, 7-H), 7.19 (1H, s, 3'-H), 7.09 (1H, ddd, J8, 6, 2, 8-H), 2.95 (3H, s, 3-CH₃), 2.73 (3H, s, 4-CH₃); m/z (%) 261 (40); ν_{max} (KBr Disc)/cm⁻¹ 3427, 1699 and 1242.

b) Ethyl 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxamide

3,4-Dimethylpyrrolo[3,2-b]carbazole-2-carboxylic acid (0.278 g, 1.0 mmol) was dissolved in dimethoxyethane (10 cm³) to give a yellow solution. To this were added diisopropylethylamine (0.260 g, 2.0 mmol), ethylamine hydrochloride (0.245 g, 3.0 mmol) and the tetrafluoroborate salt of O-benzotriazolyl-N,N,N',N'-tetramethyluronium (TBTU) (0.482 g, 1.5 mmol) to give a white suspension in the yellow solution. The reaction mixture was stirred at room temperature for 24 h by which time TLC showed no remaining acid. The solvent was removed in vacuo to give a yellow-brown solid. This was subjected to column chromatography on silica eluting firstly with DCM and then with 10% EtOAc/90% DCM to give the ethylamide product as a yellow solid (0.240 g, 79%). To remove a trace impurity, a portion was recrystallised from dichloroethane/petrol to give the compound analytically pure as a yellow powder with m.p. 235°C (decomp.) (Found: C, 73.21; H, 6.10; N, 13.33. $C_{19}H_{19}N_3O \cdot 0.1C_2H_4Cl_2$ requires: C, 73.15; H, 6.20; N, 13.32%); $\delta_H([^2H_6]-DMSO)$ 10.72 (1H, s, 1-NH), 10.57 (1H, s, 5-NH), 8.09 (1H, d, J8, 9-H), 7.93 (1H, t, J5, amide N-H), 7.83 (1H, s, 10-H), 7.27-7.41 (2H, m, 6-H, 7-H), 7.06 (1H, d, J8, 8-H), 3.35 (2H, q, J 7.5, CH₂CH₃),

2.89 and 2.71 (2 x 3H, 2 x s, 3-CH₃ and 4-CH₃), 1.18 (3H, t, J 7.5, CH₂CH₃); m/z (%) 305 (65, M⁺), 260 (100); ν_{\max} (KBr Disc)/cm⁻¹ 3314, 1603 and 1545.

c) 3,4-Dimethylpyrrolo[3,2-b]carbazole-2-carboxamide

3,4-Dimethylpyrrolo[3,2-b]carbazole-2-carboxylic acid (0.556 g, 2.0mmol) was dissolved in dimethoxyethane (20ml) to give a yellow solution. To this were added diisopropylethylamine (0.520 g, 4.0 mmol), ammonium hydrochloride (0.321 g, 6.0mmol) and the tetrafluoroborate salt of O-benzotriazolyl-N,N,N',N'-tetramethyluronium (TBTU) (0.963 g, 3.0mmol) to give a white suspension in the yellow solution. The reaction mixture was stirred at room temperature for 24 hours, by which time TLC showed no remaining acid. The solvent was removed in vacuo to give a yellow-brown solid. This was subjected to column chromatography on silica (eluting with ethyl acetate/DCM, gradient 10%-30%) to give the amide product as a yellow solid (0.350 g, 63%). To remove a trace impurity, a portion was recrystallised from ethyl acetate/petrol and then purified by preparative HPLC (column size 25 cm x 2.12 cm i.d., packed with C₈ Zorbax, gradient elution: 5% acetonitrile/95% water to 95% acetonitrile/water; detected at 340 nm) to give a yellow powder with m.p. 240°C (decomp.) δ_{H} ([²H₆]-DMSO) 10.82 (1H, s, 1-NH), 10.54 (1H, s, 5-NH), 8.08 (1H, d, J 7.5, 9-H), 7.84 (1H, s, 10-H), 7.29-7.43 (4H, m, 6-H, 7-H, NH₂), 7.07 (1H, ddd, J 8, 5.5, 2, 8-H), 2.89 and 2.85 (2 x 3H, 2 x s, 3-CH₃ and 4-CH₃); m/z (%) 277 (62, M⁺), 260 (100), 232 (44); ν_{\max} (KBr disc)/cm⁻¹ 3317, 1628, 1595; (Found: M⁺, 277.1205, C₁₇H₁₅N₃O requires 277.1215).

d) Phenyl 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxamide

3,4-Dimethylpyrrolo[3,2-b]carbazole-2-carboxylic acid (0.278 g, 1.0 mmol) was dissolved in dimethoxyethane (10ml) to give a

yellow solution. To this were added diisopropylethylamine (0.130 g, 1.0mmol), aniline (0.190 g, 2.0mmol) and the tetrafluorborate salt of O-benzotriazolyl-N,N,N',N',-tetramethyluronium (TBTU) (0.482 g, 1.5mmol) to give a white suspension in the yellow solution. The reaction mixture was stirred at room temperature for 42 hours, by which time TLC showed no remaining acid. The solvent was removed in vacuo to give a yellow solid, which was dissolved in ethyl acetate and the resulting solution washed with water. The organic layer was dried over MgSO_4 , concentrated, and subjected to column chromatography on silica, eluting with EtOAc/petrol (gradient elution 5%-100%) followed by recrystallisation from acetone to give the phenylamide product as a yellow powder (0.10 g, 30%) with m.p. 260°C (decomp.) (Found: C, 77.79; H, 5.26; N, 11.64. $\text{C}_{23}\text{H}_{19}\text{N}_3\text{O}$ requires: C, 78.16; H, 5.42; N, 11.89%); $\delta_{\text{H}}([^2\text{H}_6]\text{-DMSO})$ 11.10 (1H, s, 1-NH), 10.59 (1H, s, 5-NH), 9.96 (1H, s, amide N-H), 8.10 (1H, d, J 7.5, 9-H), 7.89 (1H, s, 10-H), 7.79 (2H, d, J 9, 2'-H, 6'-H), 7.29-7.45 (4H, m, 6-H, 7-H, 3'-H, 5'-H), 7.00-7.14 (2H, m, 8-H, 4'-H), 2.93 and 2.88 (2 x 3H, 2 x s, 3- CH_3); m/z (%) 353 (46, M^+), 260 (100); ν_{max} (KBr disc)/ cm^{-1} 3310, 1614, 1595 and 1317.

e) 3,4-Dimethyl-2-(hydrazinocarbonyl)pyrrolo[3,2-b]carbazole

Ethyl 3,4-dimethylpyrrolo[3,2-b]carbazole-2-carboxylate (500 mg) and 95% hydrazine (5 cm^3) were stirred and heated at 120°C for 6h in a Radi-Vial. The mixture was allowed to stand overnight, cooled in ice and filtered. The resulting yellow solid was washed carefully with water and dried. Yield of title compound 350mg (73%), no sharp m.p. but decomposes at 285°C . (Found: C, 69.19; H, 5.57; N, 19.38. Calc. for $\text{C}_{17}\text{H}_{16}\text{N}_4\text{O} \cdot 0.1\text{H}_2\text{O}$ requires C, 69.42; H, 5.55; N, 19.05%); $\delta_{\text{H}}([^2\text{H}_6]\text{-DMSO})$ 10.80 (1H, s, exchangeable, NH), 10.55 (1H, s, exchangeable, NH), 9.20 (1H, s, exchangeable, NH), 8.06 (1H, d, J 7.5 9-H), 7.81 (1H, s, 10-H),

7.42-7.28 (2H, m, 6-H and 7-H) 7.12-7.01 (1H, m, 8-H, 4.5 (2H, br, s, exchangeable, NH_2), and 2.4 and 2.3 (2 x s, 4- CH_3 and 3- CH_3), m/z 293 ($M+1$)⁺, FAB)].

Example 8

2-Acetyl-3,4-dimethylpyrrolo[3,2-b]carbazole

Step 1

2,4-Diacetyl-3,5-dimethylpyrrole was prepared from acetylacetone and hydroxylamine-O-sulphonic acid according to the procedure of Y. Tamura, S. Kato and M. Ikeda (Chem & Ind., 1971, 767).

Step 2

2-Acetoxyethyl-3,5-diacetyl-4-methylpyrrole

To a stirred mixture of 2,4-diacetyl-3,5-dimethylpyrrole (1.0 g), dichloromethane (35 cm³) and potassium carbonate (7.73 g) at 0-5°C was added a solution of sulphuryl chloride (0.79 g) in dichloromethane (15 cm³). The temperature of the mixture was maintained at 0.5°C during the addition by external cooling and then the mixture was stirred at this temperature until adjudged complete by t.l.c. (ca 2h). The mixture was then filtered and evaporated to give crude 2-chloromethyl-3,5-diacetyl-4-methylpyrrole. This material was dissolved in acetic acid (10 cm³), sodium acetate (1.83g) added, and then more acetic acid (10 cm³) added. The mixture was stirred overnight at room temperature, evaporated in vacuo, and the residue stirred with ice-cold water for 2h. A solid was collected by filtration and the filtrate extracted twice with ethyl acetate. The extracts were dried (MgSO_4), evaporated and the residue combined with the solid above, to give the crude product. Chromatography on silica eluting with ethyl acetate-hexane (1:1) gave 0.075 g. of pure product as an off-white solid m.p. 112.5-114.5°C; m/z 238

($M^+ + 1$, FAB), δ_H , $CDCl_3$) 2.16 (3H, s, $OCOCH_3$), 2.50 (3H, s, CH_3), 2.53 (3H, s, CH_3), 2.62 (3H, s, CH_3), 5.38 (2H, s, OCH_2).

Step 3

To a solution of 2-acetoxymethyl-3,5-diacetyl-4-methylpyrrole (0.200 g) and indole (0.098 g) in dichloroethane (90 cm³) was added Montmorillonite K10 clay (0.30 g). The mixture was stirred and heated at reflux for 80 h. After cooling the clay was removed by filtration and the filtrate concentrated to ca 20 cm³ in vacuo. The crude product was removed by filtration and then chromatographed on silica. Elution with chloroform-methanol (60:1) yielded 0.08 g of the title compound as a yellow solid m.p. 258-260°C, m/z (EI) 276 (M^+) δ_H ($[^2H_6]$ -DMSO) 2.58 (3H, s, $COCH_3$), 2.88 (3H, s, CH_3), 2.92 (3H, s, CH_3), 7.05 (1H, m, 8-H), 7.38 (2H, m, 6-H, 7-H), 7.85 (1H, s, 10-H), 8.08 (1H, J, 8 Hz, 9-H), 10.6 (1H, s, NH), 11.17 (1H, s, NH). (Found: C, 77.0; H, 5.74; N, 9.76; $C_{18}H_{16}N_2O$. 0.14 EtOAc requires C, 77.2; H, 5.98; N, 9.70%.)

Example 9

Ethyl 1,5-dihydroindeno[2,1-f]indole-2-carboxylate

Step 1

Ethyl 2-azido-3-fluoren-2-ylacrylate

Sodium (1.7eq) was added to absolute ethanol stirred under nitrogen at room temperature. When dissolution was complete the reaction was cooled to -10°C and fluorene-2-carboxaldehyde (1eq) and ethyl azidoacetate (3eq) dissolved together in the minimum of tetrahydrofuran were added dropwise. The mixture was stirred at -10°C for 20h and then quenched by the addition of

water and dichloromethane. The combined organic extracts were dried (MgSO_4) and evaporated in vacuo. Flash chromatography yielded the pure product (37%) ν_{max} (CHCl_3)/ cm^{-1} 2120 and 1765.

Step 2

Ethyl 2-azido-3-fluoren-2-ylacrylate suspended in dry toluene was heated at reflux for 1h, and the resulting solution was then evaporated to dryness in vacuo. The resulting mixture of ethyl 1,5-dihydroindino[2,1-f]indole-2-carboxylate and ethyl 1,10-dihydroindino[1,2-g]-indole-2-carboxylate was crystallised from ethanol, thus removing most of the [1,2-g] isomer and leaving the title compound (contaminated with approximately 30% of the [1,2-g]isomer) in the mother liquors which were evaporated to dryness. δ_{H} (CDCl_3) 9.11 (1H, s, br, 1-NH), 7.82-7.76 (3H, m), 7.56-7.52 (1H, m), 7.37 (H, dd, J 1 and 7), 7.34-7.28 (1H, m), 7.25 (1H, dd, J 1 and 2), 4.45 (2H, q, OCH_2CH_3), 3.97 (2H, s, CH_2) and 1.46 (3H, t, OCH_2CH_3).

Example 10

Effect of compounds of the invention in detransformation ("flattening") assay using HT1080scc2 and HT10801c cell lines.

Cell Lines and Culture Conditions

Transformed and revertant HT1080 sub-lines, HT1080scc2 and HT10801c were obtained from the Institute of Cancer Research, Chester Beatty Laboratories, Fulham Road, London. They were maintained routinely in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% foetal calf serum (FCS) and 1% penicillin/streptomycin solution containing 10,000 units per ml. All reagents were obtained from Gibco Ltd.

Cells were incubated in tissue culture grade plastic vessels at 37°C in 5 percent CO₂ in air.

Assays for compound activity

Assays for cell proliferation/cytotoxicity were carried out in tissue culture grade 96 well microtitre plates (Costar). Cells in log growth were added to the plates at a concentration of 1×10^3 cells per well on day 0 and serially diluted compounds were then added on day 1. Plates were then incubated at 37°C in 5% CO₂ in air for a further 4 days.

For quantitation of cell growth, the methylene blue biomass staining method was used, the test being read on a Multiscan plate reader at wavelength of 620nm. The morphology of the cells was checked microscopically under phase-contrast immediately before the fixation and staining with methylene blue, and by ordinary light microscopy thereafter. IC50 values for active compounds were obtained using the computer programme, GS1 and dose-response slopes were also plotted.

When compounds were tested for activity in a colony forming assay the methods used were identical to those described earlier except that serially diluted compound was added to the sloppy agar when the test was set up, and replenished at the same concentration on day 7. The test results were read on day 14.

Results

Comparative growth and morphology of HT1080scc2 and HT1080lc

Growth rates in terms of cell number were similar for both lines to day 4 but thereafter HT1080scc2 cells continued to divide to reach saturation densities approximately 2 to 3 times higher than HT1080lc by day 5.

Phenotypic differences between the 2 lines were clearly evident. HT10801c cells displayed a much flatter morphology than the transformed cells and only a few mitotic cells were seen in confluent areas of the cultures. HT1080scc2 cells however continued to divide with numerous mitotic cells visible after confluence.

Grown under anchorage independent conditions in soft agar, HT1080scc2 produced several large colonies whereas HT10801c cells failed to produce any colonies greater than 0.1mm in diameter.

Effects of selected compounds

A number of compounds of the invention were evaluated against the cell lines.

The compounds of the invention exhibited low toxicity with IC50 values in the range 50-100 μ M.


Below the results of the "flattening" assay for compounds of cell invention are shown:-

<u>Compound</u>	<u>SCC2 flattening (μM)</u>
Example 3	0.04
Example 4(a)	0.04
Example 4(b)	0.04
Example 4(f)	0.8
Example 4(e)	0.8
Example 4(h)	25
Example 4(g)	25

The compounds are effective at achieving "flattening" ie de-transformation, at levels significantly below their toxicity level.


The same compounds were also tested in assays using MCF7 human breast cancer cells, A431 epidermoid carcinoma cells and A285 melanoma cells. In all cases the compounds were effective in the range 1-5 μ M.

- 1) A compound of the formula (I)



and salts and physiologically functional derivatives thereof,

wherein A is



X is O, S, SO, SO₂, CH₂, CO or NR⁷, wherein R⁷ is H, alkyl, aralkyl, aryl, alkenyl, acyl, alkynyl, sulphonyl, or substituted sulphonyl;

Y is O, S, SO, SO₂, CH₂, CO or NR⁷;

R¹ is COR⁸, COOR⁸, CHO, CH₂OH, CH₂OR⁹, CONH₂, CONHNH¹⁰R¹¹, CONHR¹⁰, CONR¹⁰R¹¹, COO(CH₂)_nNR¹⁰R¹¹ wherein R⁸ is H, alkyl, aryl, substituted aryl or aralkyl, R⁹ is acyl or substituted acyl, R¹⁰ and R¹¹ are independently hydrogen, alkyl or aryl and n is 1 to 4;

R² is H, COOR⁸, alkyl, aryl, substituted aryl or CH₂CH₂CO₂R¹² wherein R¹² is alkyl or aryl;


R³ and R⁴ are independently H, hydroxy, alkyl, haloalkyl

alkoxy, halo, cyano, nitro, amino, alkyl amino, dialkyl amino, substituted alkyl, carboxyl or CO_2R^{12} ;

R^5 is H, alkyl, substituted alkyl, aralkyl, nitro, amino, halo, cyano, CHO or COOR^8 ;

R^6 is H, alkyl, aryl, aralkyl, nitro, halogen, CHO or COR^{13} wherein R^{13} is alkyl or aryl with the proviso that


(i) when R^2 , R^3 , R^4 , R^5 and R^6 are all H and A is



wherein Y is NH and X is O or S, then R^1 is not CO_2H or CO_2Et ;

and

(ii) when R^2 , R^3 , R^4 , R^5 and R^6 are all H and A is



wherein Y is NH, and X is O then R^1 is not CHO;

and

(iii) Y is not O when X is O.

2) A compound according to claim 1 in which

X is O, S or NR⁷, wherein R⁷ is H, alkyl, sulphonyl or toluene sulphonyl;

Y is NR⁷;

R¹ is COR⁸, COOR⁸, CH₂OR⁹, CONH₂, CONHNR^{10,11}, CONHR¹⁰, CONR^{10,11}, COO(CH₂)_nNR^{10,11} wherein R⁸ is H, alkyl, aryl, substituted aryl or aralkyl, R⁹ is acyl or substituted acyl, R¹⁰ and R¹¹ are independently hydrogen, alkyl or aryl and n is 1 to 4 carbon atoms;

R² is COOR⁸, alkyl or CH₂CH₂CO₂R¹² wherein R¹² is alkyl or aryl;

R³ and R⁴ are independently H, hydroxy, alkyl, alkoxy, halo, cyano, substituted alkyl or carboxyl;

R⁵ is H or alkyl;


R⁶ is H, alkyl or aryl; together with salts and physiologically functional derivatives thereof.

3. A compound according to claims 1 or 2 in which

X is S or NH;

Y is NH;

A is



R¹ is COOR⁸ wherein R⁸ is alkyl, or aralkyl;

R² is H or alkyl;

R³ is H, alkoxy, or halo;

R⁴ is H, alkoxy or halo;

R⁵ is alkyl;

R⁶ is hydrogen;

and salts and physiologically functional derivatives thereof.

4. A compound selected from


3-pyridyl 3,4-dimethylpyrrolo(3,2-b)carbazole-2-carboxylate;
[(3-dimethylamino)phenyl]3,4-dimethylpyrrolo(3,2-b)carbazole-2-carboxylate;
benzyl 1,3,4-trimethylpyrrolo(3,2-b)carbazole-2-carboxylate;
phenyl 3,4-dimethylpyrrolo(3,2-b)carbazole-2-carboxylate;
3,4-dimethyl-2-(1-imidazolylcarbonyl)pyrrolo(3,2-b)carbazole;
ethyl 3,4-dimethylpyrrolo(3,2-b)carbazole-2-carboxylate;
ethyl 3,4-dimethylbenzothieno(4,5-f)indole-2-carboxylate;
benzyl 3,4-dimethylpyrrolo(3,2-b)carbazole-2-carboxylate;
benzyl 8-fluoro-3,4-dimethylpyrrolo(3,2-b)carbazole-2-carboxylate;
ethyl 8-fluoro-3,4-dimethylpyrrolo(3,2-b)carbazole-2-carboxylate;
benzyl 3,4,6-trimethylpyrrolo(3,2-b)carbazole-2-carboxylate;
ethyl 3,4,6-trimethylpyrrolo(3,2-b)carbazole-2-carboxylate;
8-fluoro-3,4-dimethylpyrrolo(3,2-b)carbazole-2-carboxylic acid;
3,4-dimethylpyrrolo(3,2-b)carbazole-2-carboxylic acid;
ethyl 8-methoxy-3,4-dimethylpyrrolo(3,2-b)carbazole-2-carboxylate;
3,4,6-trimethylpyrrolo(3,2-b)carbazole-2-carboxylic acid; and
benzyl 8-methoxy-3,4-dimethylpyrrolo(3,2-b)carbazole-2-carboxylate;

and salts and physiologically functional derivatives thereof

5. A pharmaceutical formulation which comprises a compound of formula (I) according to claim 1 together with a pharmaceutically acceptable carrier thereof.

6. A compound of formula (I) according to claims 1 to 4 for use in medicine.
7. Use of a compound of formula (I) or a pharmaceutically acceptable salt or physiologically functional derivative thereof for the manufacture of a medicament for the treatment of tumours.
8. A method of treatment of tumours in animals, which comprises the administration of an effective amount of a compound of formula (I) or a salt or physiologically functional derivative thereof.
9. A process for preparing compounds of general formula (I) as described in claim 1 which process comprises :

(a) catalysed ring closure of compounds of formula (IV) in the presence of a strong acid



wherein X, Y, R¹, R², R³, R⁴ and R⁵ are as defined herein; or

(b) conversion of one compound of formula (I) into another compound of formula (I).

10. Novel intermediates of formula (II), (III), (IV) or (V)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 93/01512

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07D487/04 C07D495/04 C07D207/34 C07D403/06 C07D209/58
A61K31/40 //(C07D487/04, 209:00, 209:00)
(C07D495/04, 307:00, 209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	S. BUDAVARI 'THE MERCK INDEX, 11TH EDITION' 1989, MERCK & CO, RAHWAY, N.J., US see monograph numbers 4869, 4851, 1098 ---	10
X	JOURNAL OF HETEROCYCLIC CHEMISTRY. vol. 29, no. 2, March 1992, PROVO US pages 305 - 309 G. SPADONI ET AL 'Short synthesis of tryptophane and beta-carboline derivatives by reaction of indoles with N-(diphenylmet hylene)-alpha,beta-didehydroamino acid esters' see compounds 1a-f ---	10
X	EP,A,0 300 688 (FISONS) 25 January 1989 see claim 1; example 15 --- -/--	10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

26 October 1993

Date of mailing of the international search report

18. 11. 93

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

VOYIAZOGLU, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 93/01512

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 69, no. 25, 1968, Columbus, Ohio, US; abstract no. 106398a, V. N. LUZGINA ET AL 'Synthetic studies in dipyrromethanes. Synthesis of asymmetric 3',4-dimethyl-3,4'-bis(alpha-hydroxyethyl) -5-carbobenzoxydipyrromethane' page 9959 ; see abstract & ZH. OBSHCH. KHIM. vol. 38, no. 6 , 1968 pages 1372 - 1375 ---	10
X	CHEMICAL ABSTRACTS, vol. 78, no. 17, 1973, Columbus, Ohio, US; abstract no. 111048b, A. F. MIRONOV ET AL 'Synthesis and some reactions of pyrroles with aliphatic acyl substituents' page 460 ; see abstract & KHIM. GETEROTSIKL. SOEDIN no. 1 , 1973 pages 27 - 30 ---	10
X	CANADIAN JOURNAL OF CHEMISTRY. vol. 56, no. 18 , 1978 , OTTAWA CA pages 2430 - 2436 see page 2433, scheme 3 ---	10
X	CHEMICAL ABSTRACTS, vol. 103, no. 7, 1985, Columbus, Ohio, US; abstract no. 53975y, T. KHOSHTARIYA ET AL 'Indolobenzo(b)furans. 2. Some derivatives of indolo(5,6-d) and indolo(5,4-d)benzo(b)furans' page 570 ; cited in the application see abstract & KHIM. GETEROTSIKL. SOEIDN. no. 3 , 1985 pages 355 - 358 --- -/--	10

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 95, no. 11, 1981, Columbus, Ohio, US; abstract no. 97622b, L. A. KINTSURASHVILI ET AL 'Indolobenzothiophenes. 2. Some electrophilic substitution reactions of indolo(6,5-d)benzothiophene' page 638 ; see abstract & KHIM. GETEROTSIKL. SOEDIN. no. 2 , 1981 pages 211 - 214 ---	10
X	EP,A,0 447 703 (THE WELLCOME FOUNDATION LIMITED) 25 September 1991 cited in the application see claims 1,9,10 ---	1,5,7
P,X	JOURNAL OF CHEMICAL RESEARCH, SYNOPSES no. 8 , August 1992 , LONDON, GB pages 258 - 259 L. CHUNCHATPRASERT ET AL 'A clay-catalysed synthesis of mono- and di-pyrrolylmethylindoles and evidence for a 3,3-di(pyrrolylmethyl)indole intermediate' see the whole document ---	10
P,X	JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1. no. 14 , 21 July 1992 , LETCHWORTH GB pages 1779 - 1783 L. CHUNCHATPRASERT ET AL 'A new synthetic route to pyrrolo(3,2-b)carbazoles, 1H-benzofuro(3,2-f)indoles and 1H-(1)benzothieno(2,3-f)indoles' see the whole document ---	1,10
A	FR,A,2 655 345 (TOYAMA CHEMICAL) 7 June 1991 see claims 1,43,44 -----	1,5,7

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB93/01512

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 8 is directed to a method of treatment (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 93/01512

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0300688	25-01-89	JP-A- 1061455	08-03-89
EP-A-0447703	25-09-91	WO-A- 9114688	03-10-91
FR-A-2655345	07-06-91	BE-A- 1004069	15-09-92
		CA-A- 2028960	02-05-91
		CH-A- 682151	30-07-93
		DE-A- 4034687	02-05-91
		GB-A, B 2239013	19-06-91
		JP-A- 4178387	25-06-92
		NL-A- 9002366	03-06-91
		SE-A- 9003476	01-05-92
		US-A- 5166204	24-11-92